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Abstract 
 
Context and Rationale: The incidence of HIV in Saskatchewan is the highest in 
Canada and the epidemiology in this province is unique. Clinically, rapid decline in 
CD4+ cell count and rapid progression to AIDS has been reported. The high proportion 
of co-morbidities present in this population could offer some explanation for this 
accelerated progression. The purpose of this study was to assess the impact of selected 
cofactors on the rate of CD4+ count change as well as to identify factors associated 
with an increased risk of rapid CD4+ count decline among HIV-infected adults in 
Saskatoon, Saskatchewan.  
 
Methods: This is a retrospective longitudinal cohort study from a medical chart review 
at the Positive Living Program and the Westside Community Clinic in Saskatoon. 
Study inclusion criteria included HIV diagnosis between January 1st, 2003 and 
November 30th, 2011 and at least 18 years of age at time of diagnosis. Multiple 
statistical analyses were used to assess the influence of selected cofactors on changes 
in CD4+ count over time, including linear regression, mixed effects models and logistic 
regression.  
 
Results: In total 457 patients were eligible for inclusion in the study. The mean follow-
up time was 46.3 (SD = ± 26.8) months.  
 
When CD4+  slope was estimated by linear regression patients who were not prescribed 
ARV during the follow-up period had a significantly higher CD4+ at diagnosis as 
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compared to patients who were prescribed ARV (p<0.0001). Hepatitis C infection 
(HCV) (p=0.0079), a history of injection drug use (IDU) (p=0.0002), a record of 
incarceration (p=0.016) and not having been prescribed antiretroviral therapy (ARV) 
during the follow-up period (p=0.0004) were associated with a significantly more rapid 
decline in CD4+ count.  
 
Due to high association between First Nation or Métis ethnicity, HCV-coinfection and 
IDU three separate multivariate mixed effects models were built. In the model 
including First Nations or Métis ethnicity, First Nations or Métis ethnicity (p=0.028), 
receipt of social assistance (p=0.011) and age at diagnosis (p=0.0011) were 
significantly associated with CD4+ count. Receipt of ARV over time was significantly 
associated with a rise in CD4+ count (p=0.0089). In another model including HCV co-
infection, HCV co-infection (p=0.0048) and age at diagnosis (p=0.039) were 
significantly associated with CD4+ count. Receipt of ARV over time (p=0.0004) was 
again associated with an increase in CD4+ count. Finally, in the third model, which 
included history of IDU, history of IDU (p=0.047), receipt of social assistance 
(p=0.042) and age at diagnosis (p=0.018) were significantly associated with CD4+ 
count. Receipt of ARV over time (p=0.001) was associated with an increase in CD4+ 
count.  Model 1 had the lowest AIC value. 
 
Only CD4+ counts recorded while patients were not receiving ARV were included in 
the logistic regression analysis. Two subpopulations were analyzed in these models, 
patients with an initial CD4+ of ! 500 cells/mm3 and patients with an initial CD4+ count 
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of ! 300 cells/mm3. CD4+ count slopes were estimated using both linear regression and 
mixed effects models. In the logistic regression models of subgroups which consisted 
of patients with the 25% steepest and 25% shallowest CD4+ count slopes, ARV was 
consistently significantly associated with experiencing rapid CD4+ count decline.  
 
Conclusion: HCV co-infection, a history of IDU, a record of incarceration and not 
receiving ARV during the follow-up period were associated with a significantly more 
rapid CD4+ count decline. First Nations ethnicity, HCV and IDU are highly correlated, 
therefore the effects of each of these variables on CD4+ count are likely not 
independent. Overall among all three multivariate mixed effects models, First Nation 
or Métis ethnicity, HCV co-infection, a history of IDU, receipt of social assistance, and 
age at diagnosis were associated with lower CD4+ cell count, whereas ARV treatment 
was associated with increasing counts. In the logistic regression models receipt of 
ARV was associated with rapid CD4+ count decline. Individuals exhibiting factors 
associated with rapid CD4+ count decline or lower CD4+ counts over the follow-up 
period could benefit from more frequent follow-up by clinicians and earlier initiation 
of ARV. Increased attention and resources focused on this population are needed to 
prevent disease progression.  
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1. Introduction 
 
1.1 Study Rationale 
The epidemic of Human Immunodeficiency Virus (HIV) has been growing at an 
alarming rate in the province of Saskatchewan since 2003 (1,2,2).  Despite this 
troublesome trend, limited research has been dedicated to the study of this high risk and 
underserved HIV-infected population.  
The HIV positive population of Saskatchewan is afflicted by many health-
compromising conditions, including Hepatitis C (HCV), illicit injection drug use (IDU), 
mental illness and circumstances associated with poverty, including homelessness and 
malnutrition.  
In Saskatchewan and throughout Canada, populations of people of First Nations, 
Métis and Inuit ethnicity are over-represented among cases of HIV and AIDS (1,3,4). 
This marginalized ethnic group also faces the challenges of lower educational attainment, 
lower rates of employment, lower median annual income, reduced life expectancy and 
overall poorer health when compared with the rest of the Canadian population (3).  
Evidence of rapid progression to immunologic AIDS (defined as a CD4+ count 
below 200 cells/ mm3) in Saskatchewan is of particular concern. The HIV positive 
population of Saskatchewan is afflicted with a multitude of health-compromising 
conditions, is understudied and is showing evidence of rapid progression to AIDS. 
Studies which seek ultimately to prolong and elevate the quality of life of HIV infected 
individuals are urgently needed in this province. The university environment provides an 
advantaged perspective from which we are charged with a responsibility to study and 
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ultimately to assume an important role in the mitigation of the HIV epidemic in this 
province.  
 
1.2 Study Purpose 
The purpose of this study is to determine clinical and social factors that are 
associated with faster or slower rates of change in CD4+ count among HIV infected adults 
in Saskatoon, Saskatchewan. The results of this study will lead to improvements in the 
quality of clinical care provided to HIV infected individuals in this community. 
 
1.3 Research Objectives 
(1) To estimate the overall average rate of CD4+ count depletion over the follow-up 
period; specifically the differences in rates among the following groups will be 
investigated: Age at diagnosis; Gender; Ethnicity; HCV co-infection; History of IDU; 
antiretroviral therapy (ARV); Incarceration during follow-up; Individuals engaged in case 
management services; Individuals receiving social assistance; Individuals infected with 
an STI.  
(2) To determine the effects of the clinical and social factors listed in objective 1 on 
CD4+ cell count changes.   
(3) To identify subjects showing  “rapid”- CD4+ cell count decline, and to determine 
clinical and social factors associated with this designation. Rapid decline will be defined 
by the slope of CD4+ count for each individual. 
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1.4. Study Hypotheses 
Based on our study objectives we present here the hypotheses for our study. 
1.4.1. Objective 1 Hypotheses 
Age H0: There is no difference in mean CD4+ count (cells/mm3) at diagnosis and 
mean CD4+count slope (cells/mm3 per month) over the follow-up period between 
patients diagnosed HIV positive above the mean age at diagnosis among this 
cohort, as compared to patients below it. 
HA: There is a difference in either mean CD4+ count (cells/mm3) at diagnosis or 
mean CD4+count slope (cells/mm3 per month) over the follow-up period, or both 
between patients diagnosed HIV positive above the mean age at diagnosis among 
this cohort, as compared to patients below it. 
  
Gender H0: There is no difference in mean CD4+ count (cells/mm3) at diagnosis 
and mean CD4+count slope (cells/mm3 per month) over the follow-up period 
between males and females.  
HA: There is a difference in either mean CD4+ count (cells/mm3) at diagnosis or 
mean CD4+count slope (cells/mm3 per month) over the follow-up period between 
males and females. 
 
Ethnicity H0: There is no difference in mean CD4+ count (cells/mm3) at diagnosis 
and mean CD4+count slope (cells/mm3 per month) over the follow-up period 
between patients who self-identify as of First Nations or Métis ethnicity as 
compared to patients who do not.  
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HA: There is a difference in either mean CD4+ count (cells/mm3) at diagnosis or 
mean CD4+count slope (cells/mm3 per month) over the follow-up period between 
patients who self-identify as of First Nations or Métis ethnicity as compared to 
patients who do not.  
 
HCV H0: There is no difference in mean CD4+ count (cells/mm3) at diagnosis and 
mean CD4+count slope (cells/mm3 per month) over the follow-up period between 
patients who were co-infected with HCV as compared to those who were not.  
HA: There is a difference in either mean CD4+ count (cells/mm3) at diagnosis or 
mean CD4+count slope (cells/mm3 per month) over the follow-up period between 
patients who were co-infected with HCV as compared to those who were not.  
 
IDU H0: There is no difference in mean CD4+ count (cells/mm3) at diagnosis and 
mean CD4+count slope (cells/mm3 per month) over the follow-up period between 
patients who had a history of IDU as compared to those who did not.  
HA: There is a difference in either mean CD4+ count (cells/mm3) at diagnosis or 
mean CD4+count slope (cells/mm3 per month) over the follow-up period between 
patients who had a history of IDU as compared to those who did not.  
 
Incarceration H0: There is no difference in mean CD4+ count (cells/mm3) at 
diagnosis and mean CD4+count slope (cells/mm3 per month) over the follow-up 
period between patients who were incarcerated during the follow-up period as 
compared to those who were not.  
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HA: There is a difference in either mean CD4+ count (cells/mm3) at diagnosis or 
mean CD4+count slope (cells/mm3 per month) over the follow-up period between 
patients who were incarcerated during the follow-up period as compared to those 
who were not.  
 
Social Assistance H0: There is no difference in mean CD4+ count (cells/mm3) at 
diagnosis and mean CD4+count slope (cells/mm3 per month) over the follow-up 
period between patients who received social assistance as compared to those who 
did not. 
HA: There is a difference in either mean CD4+ count (cells/mm3) at diagnosis or 
mean CD4+count slope (cells/mm3 per month) over the follow-up period between 
patients who received social assistance as compared to those who did not. 
 
Case Management H0: There is no difference in mean CD4+ count (cells/mm3) at 
diagnosis and mean CD4+count slope (cells/mm3 per month) over the follow-up 
period between patients who were Case Management clients as compared to 
patients who did not access such services.  
HA: There is a difference in either mean CD4+ count (cells/mm3) at diagnosis or 
mean CD4+count slope (cells/mm3 per month) over the follow-up period between 
patients who were Case Management clients as compared to patients who did not 
access such services.  
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STI H0: There is no difference in mean CD4+ count (cells/mm3) at diagnosis and 
mean CD4+count slope (cells/mm3 per month) over the follow-up period between 
patients who were diagnosed with an STI during the follow-up period as 
compared to patients who did not receive such a diagnosis.  
HA: There is a difference in either mean CD4+ count (cells/mm3) at diagnosis or 
mean CD4+count slope (cells/mm3 per month) over the follow-up period between 
patients who were diagnosed with an STI during the follow-up period as 
compared to patients who did not receive such a diagnosis.  
 
ARV H0: There is no difference in mean CD4+ count (cells/mm3) at diagnosis and 
mean CD4+count slope (cells/mm3 per month) over the follow-up period between 
patients who were prescribe ARV during the follow-up period as compared to 
those who were not.  
HA: There is a difference in either mean CD4+ count (cells/mm3) at diagnosis or 
mean CD4+count slope (cells/mm3 per month) over the follow-up period between 
patients who were prescribe ARV during the follow-up period as compared to 
those who were not.  
 
1.4.2. Objective 2 Hypotheses 
 H0: None of the social or clinical factors listed in Objective 1 will have any 
significant influence on CD4+ count changes (cells/mm3 per month) over the 
follow up period. 
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HA: At least one of the social or clinical factors listed in Objective 1 will have a 
significant influence on CD4+ count changes (cells/mm3 per month) over the 
follow up period.  
 
1.4.3. Objective 3 Hypotheses  
 Age H0: The odds of rapid CD4+ cell count (cells/mm3 per month) decline are the 
same among patients who are older as compared to patients who are younger at 
HIV diagnosis. 
HA: The odds of rapid CD4+ cell count (cells/mm3 per month) decline are 
significantly greater or lesser among patients who are older as compared to 
patients who are younger at HIV diagnosis. 
 
 Gender H0: The odds of rapid CD4+ cell count (cells/mm3 per month) decline are 
the same among males as compared to females. 
HA: The odds of rapid CD4+ cell count (cells/mm3 per month) decline are 
significantly greater or lesser among males as compared to females. 
 
Ethnicity H0: The odds of rapid CD4+ cell count (cells/mm3 per month) decline 
are the same among patients who self-identify as of First Nations or Métis 
ethnicity as compared to those who do not.  
HA: The odds of rapid CD4+ cell count (cells/mm3 per month) decline are 
significantly greater or lesser among patients who self-identify as of First Nations 
or Métis ethnicity as compared to patients who do not.  
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HCV H0: The odds of rapid CD4+ cell count (cells/mm3 per month) decline are 
the same among patients who were HCV co-infected as compared to patients who 
were not.  
HA: The odds of rapid CD4+ cell count (cells/mm3 per month) decline are 
significantly greater or lesser among patients who were HCV co-infected as 
compared to patients who were not.  
 
IDU H0: The odds of rapid CD4+ cell count (cells/mm3 per month) decline are the 
same among patients who had a history of IDU as compared to patients who did 
not.  
HA: The odds of rapid CD4+ cell count (cells/mm3 per month) decline are 
significantly greater or lesser among patients who had a history of IDU as 
compared to patients who did not.  
 
Incarceration H0: The odds of rapid CD4+ cell count (cells/mm3 per month) 
decline are the same among patients who were incarcerated during the follow-up 
period as compared to those who were not.  
HA: The odds of rapid CD4+ cell count (cells/mm3 per month) decline are 
significantly greater or lesser among patients who were incarcerated during the 
follow-up period as compared to those who were not.  
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Case Management: H0: The odds of rapid CD4+ cell count (cells/mm3 per 
month) decline are the same among patients who were Case Management clients 
as compared to patients who were not.  
HA: The odds of rapid CD4+ cell count (cells/mm3 per month) decline are 
significantly greater or lesser among patients who were Case Management clients 
as compared to patients who were not.  
 
Social Assistance: H0: The odds of rapid CD4+ cell count (cells/mm3 per month) 
decline are the same among patients who were recipients of social assistance as 
compared to patients who were not.  
HA: The odds of rapid CD4+ cell count (cells/mm3 per month) decline are 
significantly greater or lesser among patients who were recipients of social 
assistance as compared to patients who were not.  
 
STI H0: The odds of rapid CD4+ cell count (cells/mm3 per month) decline are the 
same among patients who were diagnosed with an STI during the follow-up 
period as compared to patients who were not.  
HA: The odds of rapid CD4+ cell count (cells/mm3 per month) decline are 
significantly greater or lesser among patients who were diagnosed with an STI 
during the follow-up period as compared to patients who were not. 
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ARV H0: The odds of rapid CD4+ cell count (cells/mm3 per month) decline are 
the same among patients who were recipients of ARV as compared to patients 
who were not.  
HA: The odds of rapid CD4+ cell count (cells/mm3 per month) decline are 
significantly greater or lesser among patients who were recipients of ARV as 
compared to patients who were not.  
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2. Literature Review 
2.1. HIV/AIDS 
Acquired Immunodeficiency Syndrome (AIDS) was first identified in 1981 based on 
the diagnosis of Kaposi’s sarcoma (KS) and Pneumocystic carinii pneumonia (PCP) in 
previously healthy homosexual men living in Los Angeles, California and New York, 
New York (5). By 1989 AIDS was recognized as an endemic life-threatening condition 
among vulnerable sub-populations namely, sex workers and their clients, men who have 
sex with men (MSM) and IDUs (6,7). In the developed countries of the world the HIV 
epidemic has mostly been confined to populations of IDU and MSM (7). In the early 
years of the epidemic MSM was the most severely affected population. The successful 
mobilization by this population against the disease resulted in a significant decrease in 
incident cases after the mid-1980s (7). The most prominent feature of the HIV/AIDS 
epidemic in the developed world is undoubtedly the development of ARV, which has 
substantially decreased AIDS related mortality and has enabled infected individuals to 
lead healthy and productive lives.  
 Approximately 95% of individuals ever infected with HIV are living or previously 
lived in developing countries (8). In 2010 greater than 60% of infected individuals lived 
in sub-Saharan Africa (7-9). The majority of infected individuals are of economically 
productive age and are thereby likely responsible for supporting both their children and 
elderly relatives (10). Due to the low levels of financial resources available in developing 
countries, most infected individuals will receive minimal care when they themselves 
develop AIDS (7). Additional barriers faced in the mitigation of the HIV epidemic are 
 12 
that efforts to prevent HIV transmission raise universally culturally sensitive issues of 
sexuality, gender inequality, commercial sex, MSM and IDU (7).  
At the conclusion of 2010, the HIV epidemic had killed more than 25 million people 
with an additional 34 million people living with HIV worldwide (8). HIV is transmitted 
through sexual contact, both heterosexual and homosexual, by blood and by vertical 
transmission from mother to infant (11). Sexual contact is the predominant mode of 
transmission globally (7).  
After initial infection many individuals remain asymptomatic for years (11). A small 
proportion of individuals (10-20%) have symptoms of an acute illness at the time of 
infection (11). Without effective ARV intervention, infection with HIV ultimately results 
in the development of AIDS, usually within 8 to 12 years of seroconversion (the time at 
which HIV antibodies become detectable in the infected patients’ blood) (12-14). AIDS 
results when the immune system is weakened to a point at which it is no longer able to 
maintain control of the HIV virus (15). In Canada an AIDS diagnosis includes a positive 
result on an HIV test in addition to infection with one or more AIDS-defining illnesses 
(16).  
Presently, there is neither cure, nor vaccine available for HIV. The advent of ARV, at 
least in developed countries, has however dramatically increased the lifespan of HIV 
infected individuals and transformed HIV infection from a likely death sentence to a 
chronic condition (17). Encouragingly, between 2003 and 2010 there was a 16-fold 
increase in the number of people receiving ARV in low- and middle-income countries 
(8). In spite of this promising trend, effective ARV remains unavailable in many parts of 
the world where the spread and impact of HIV/AIDS is the most devastating (18).  
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2.2. CD4+ T-Lymphocyte Cells and HIV Disease Progression 
HIV propagates itself in the human body through integration into the genome of 
CD4+ cells (11,15). CD4+ cells have a central role in the immune system crucial to the 
coordination of cellular and humoral immune responses to foreign antigens (15). Immune 
deficiency in AIDS is caused by the virally mediated destruction of CD4+ T-cells (11,13). 
The loss of CD4+ cell activity compromises the function of other types of immune cells 
(11). The HIV virus assumes control of the cellular machinery of the CD4+ cells to 
manufacture copies of itself, which go on to infect other CD4+ cells. Therefore, HIV 
disease progression is characterized by the progressive decline in CD4+ count over time 
since infection (13,15,19-21). The average CD4+ count of an HIV negative individual 
with a healthy immune system is between 800 and 1,200 cells/ mm3 (13). Monitoring 
CD4+ cell counts over time provides a surrogate measure of HIV disease progression 
(11). Advanced HIV disease can be identified by low CD4+ cell counts and the presence 
of HIV related symptoms associated with high viral loads (20). The most commonly 
observed pattern of change in CD4+ count is an initial steep decline following 
seroconversion, slowing over time until a plateau is reached (11,21,23). Viral load 
dynamics have also been suggested to be of importance in influencing CD4+ count (24-
26). A higher viral load has been correlated with a higher rate of CD4+ count decline 
(26).  CD4+ count is commonly used as an end point in clinical studies of new therapies 
and importantly is used by clinicians in determining when to initiate ARV and other 
prophylactic therapies in the treatment of opportunistic infections (11,13,27,28).  
Figure 1.1. depicts the average natural course of HIV infection with respect to the 
decline in CD4+ count and corresponding increase in viral load. During the initial four to 
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eight weeks following virus entry (primary HIV infection) there is an explosive increase 
in HIV viral load (29-32). This spike in viral load is down regulated when the host’s 
immune system mounts a partially effective immune response against the virus, 
characterizing the chronic phase of HIV infection (29-32). The immune system remains 
in a chronic activation stage typically for several years until it is no longer able to 
maintain control of the HIV virus resulting in an increase in viral load and in 
susceptibility to other microbial infections (33).  These events signal the end of the 
chronic phase and the development of AIDS.    
Figure 1.1. Average natural course of HIV infection over time as measured by CD4+ count and viral load.  
 
Source: HIV/AIDS Clinical Features, http://www.dwp.gov.uk/publications/specialist-guides/medical-
conditions/a-z-of-medical-conditions/hiv-aids/clinical-features/(34)  
 
Median time from seroconversion to AIDS diagnosis, without effective ARV 
intervention, is 10 years (35). An annual decline of 60 cells/!L based on an initial count 
 15 
of 800 cells/ !L among ARV naive patients has been estimated (22). However, much 
heterogeneity exists in the rate of the clinical course of HIV infection. At one extreme are 
patients designated as long-term nonprogressors (LTNPs) or long-term asymptomatics 
(LTA) (15,36). Such individuals represent the estimated 5% of HIV-1 infected people 
who maintain a normal CD4+ count and an undetectable viral load in the absence of ARV 
more than 10 years following infection (15). At the other extreme are rapid progressors, 
the estimated 20% of individuals developing AIDS within 5 years of infection or having a 
time from seroconversion to a CD4+ count below 200 cells/mm3 of less than 7.5 years 
(36-38). A high initial viral load followed by further increase in viral load has also been 
found to be characteristic of rapid progression (21).  
Immune activation has been identified as probably the most important 
determinant of variations in HIV-1 disease progression (18). Patients with high levels of 
T-cell activation at presentation are at a heightened risk for rapid CD4+ decline (25). The 
activation of host immune cells (primarily CD4+ cells, macrophages and dendritic cells) 
in conjunction with co-infection with acute infectious illnesses may enhance HIV viral 
replication and consequently accelerate CD4+ cell decline (18,33,39). Accelerated decline 
in CD4+ count is associated with a shortened time to AIDS diagnosis (21). Rapid decline 
has been identified as a decline in CD4+ count of more than 100 to 140 cell/mm3 per year 
(9,15,36). Therefore, patients with the most extensive or rapid decline in CD4+ cell levels 
are also the most likely to develop AIDS earlier (11).  
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2.3. Epidemiology of HIV in Canada 
In the HIV and AIDS in Canada Surveillance Report to December 31, 2009 the 
Public Health Agency of Canada (PHAC) documented a cumulative total of 69,844 
positive HIV tests in Canada between 1985 and December 31st, 2009 (1). A total of 
21,681 AIDS cases have been reported to PHAC between 1979 and December 31st, 2009. 
A cumulative total of 16, 452 deaths among adults have been attributed to HIV infection 
between 1987 and 2006.  
The two most prominent historical features of the HIV epidemic in Canada are the 
initial peak in incidence primarily among MSM at the beginning of the epidemic (1984-
1985) and the subsequent development of ARV (4). The number of cases of HIV reported 
to PHAC over the past 10 years has remained relatively stable. The incidence of positive 
HIV tests among adults in Canada in 2009 was 8.6 per 100,000.  
MSM has remained the most commonly reported exposure over the entire course 
of the epidemic. However, the reporting of this exposure has declined over time, from 
80% of cases in 1985 to 41.8% of cases in 2009, while the proportion attributed to IDU 
has increased, to a peak in 2007 of 33.5% of cases reporting this exposure (see Figure 
1.2). In 2009, heterosexual contact was the second most commonly reported exposure 
category at 30.7% of incident cases, with IDU being the third most reported at 21.6% of 
cases.  
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Figure 1.2. Estimated exposure category of new HIV infections in Canada, 1981-2008.  
 
Source: HIV/ AIDS Epi Update Public Health Agency of Canada. July 2010. (4) 
 
 
The number of cases among females has increased steadily since 1985. In 2009, 
26 % of incident cases were reported among females (see Figure 1.3).  
 
Figure 1.3. Proportion of new positive HIV tests by sex  in Canada, 1985-2009.  
 
Source: Public Health Agency of Canada. HIV and AIDS in Canada. Surveillance Report to December 31, 
2009 (1).  
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With respect to age distribution, the 30-39 age range has encompassed the largest 
proportion of HIV case reports since 1985. Since 2000, the proportion of cases reported 
in the age range of 40-49 and over 50 has increased, while the proportion of cases 
reported in the 30-39 age range has decreased. For a summary of age trends among HIV 
cases see Figure 1.4. Since 1985, cases reported among females have generally occurred 
more often in the younger age groups whereas cases among males have been most often 
reported among the older age groups.  
Figure 1.4. Proportion of new positive HIV tests by age group in Canada, 2000 -2009.  
 
Source: Public Health Agency of Canada. HIV and AIDS in Canada. Surveillance Report to December 31, 
2009 (1).  
 
When considering the distribution of ethnicities of new HIV cases it is noteworthy 
that in 2009 67.1% of cases were not accompanied by any ethnic status or race 
information. Among cases where information on ethnicity was available, the majority of 
cases were among individuals of White (44.2%), First Nations, Métis or Inuit (33.3%), 
and Black ethnicity (11.6%).  
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2.4. Epidemiology of HIV Among First Nations, Métis and Inuit Peoples in Canada 
As documented by the PHAC Population Specific HIV/AIDS Status Report on 
Aboriginal People, First Nations, Métis and Inuit peoples are over-represented among the 
HIV-infected population in Canada (3). While this ethnic group represented only 3.8% of 
the total Canadian population (1.1 million people) on the 2006 census, this group 
represented 8% (4,300 to 6,100) of all people living with HIV and 12.5% (300 to 520) of 
incident infections in 2008. Many factors increase the vulnerability of this population to 
HIV infection, including increased rates of poverty, homelessness, violence, racism and 
the lasting effects of colonialism and the residential school system. It is important to 
acknowledge that First Nations, Inuit and Métis people do not comprise a homogeneous 
group, but rather represent distinct populations with unique cultural, linguistic, 
geographic and historic characteristics. 
First Nations, Métis and Inuit peoples are more likely to be diagnosed with HIV at 
a younger age (40).  In addition, a greater proportion of First Nations, Métis and Inuit 
women are infected as compared with other ethnic groups, as between 1998 and 2006 
females comprised 48.1% of incident cases among First Nations, Métis and Inuit people, 
while only 20.7% of cases occurred among females in Canada’s non-aboriginal 
population (40). IDU is the most commonly reported exposure among this ethnic group 
with women more often reporting this exposure than men.  The second most commonly 
reported exposure category among both genders is heterosexual contact. Importantly, 
First Nations, Métis or Inuit IDU represent the fastest growing population of incident 
cases of HIV in Canada.    
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2.5. Epidemiology of HIV in Saskatchewan 
In 2009 the incidence of HIV in Saskatchewan (23.6 per 100,000) exceeded the 
national average (of 8.6 per 100,000) by almost 3-fold, as well as more than doubled that 
of the province of Ontario, with the second highest incidence in Canada at 9.3 (1). Of 
further concern is the dramatic increase in reported cases in recent years from 26 cases in 
2002 to a peak of 200 in 2009 (see Figure 1.5). This increase prompted the creation of the 
‘HIV Strategy for Saskatchewan’ by the Saskatchewan Ministry of Health (2,41).  
 
Figure 1.5. Incidence of HIV in Saskatchewan as compared to the national incidence, 2001-2010.  
 
Source: HIV and AIDS in Saskatchewan 2010, Annual Report prepared by Disease Prevention Unit, 
Population Health Branch, Saskatchewan Ministry of Health (41).   
 
As documented in the annual report on HIV and AIDS in Saskatchewan published 
by the Saskatchewan Ministry of Health on November 30, 2011, the past 3 years have 
seen the highest incidences of HIV in the history of the province, 16.7 in 2008, 19.3 in 
2009 and 16.1 in 2010 (per 100 000). This indicates that the HIV epidemic in 
Saskatchewan is far from its resolution. While the national rate of HIV has remained 
stable over the past decade, rates in Saskatchewan have been consistently increasing 
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since 2002, surpassing the national rate in 2006 and remaining consistently higher (see 
Figure 1.5) (1,41). The cost to the provincial health care system has been estimated at 
more than $ 40 million annually (2). 
 The majority of cases have occurred in the health regions incorporating 
Saskatchewan’s largest urban centers. Between 2004 and 2010, 45% of HIV cases were 
reported in the Saskatoon Health Region (SHR), 26 % in the Regina Qu’Appelle Health 
Region and 12 % in the Prince Albert Parkland Health Region.  
From 2001 to 2010 55% of cases have occurred among men. This is a 
significantly lower proportion as compared to the 73.6% of cases reported at the national 
level among men as of 2008 (4). With respect to reported age at diagnosis in 
Saskatchewan, recent years have seen a rise in the number of cases among older males 
and among younger females.  
 There are many aspects of the HIV epidemic in Saskatchewan that make it unique 
in Canada, even as compared to the neighboring provinces of Alberta and Manitoba (42). 
For example, while IDU-attributed HIV exposure has declined on the national scale, 
Saskatchewan has reported significant increases in this exposure category (1). Self-
reporting of IDU as the primary HIV exposure increased from 30 % of cases in 2001 to 
79 % in 2009 (see Figure 1.6). While MSM has been and continues to be the predominant 
mode of exposure on the national scale, MSM has not been identified as a significant risk 
factor for HIV transmission in Saskatchewan (1,41). Another unique aspect is the number 
of individuals of First Nations and Métis ethnicity represented in this epidemic (see 
Figure 1.7). In 2010, 73% of incident cases were reported among this ethnic group (41).  
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Figure 1.6. Attributable risk factors among incident HIV cases in Saskatchewan, 2001 -2010.
 
Source: HIV and AIDS in Saskatchewan 2010, Annual Report prepared by Disease Prevention Unit, 
Population Health Branch, Saskatchewan Ministry of Health (41).   
 
Figure 1.7. Incident cases among patients of First Nations, Métis and Inuit ethnicity as compared to other 
ethnicities in Saskatchewan, 2001-2010.  
 
 
Source: HIV and AIDS in Saskatchewan 2010, Annual Report prepared by Disease Prevention Unit, 
Population Health Branch, Saskatchewan Ministry of Health (41).   
 
Since AIDS became a reportable disease in 1984, 298 cases  (238 among males 
and 60 among females) had been recorded provincially as of 2010. Since 2004, 75% of 
deaths attributable to AIDS have been among males.  
 23 
 In a panel discussing the HIV epidemic in Saskatchewan organized on February 
14th, 2011 by the Community Health and Epidemiology student group Community Health 
for Community Change, the challenges faced in the mitigation of the HIV epidemic in the 
province were explored and some of the topics that arose from this discussion are 
presented here (42). The unique characteristics of the HIV epidemic in Saskatchewan not 
only makes it unique in Canada but also makes it one of the most difficult populations to 
treat nationally. IDUs, for example may be among the members of society in the poorest 
of health but frustratingly for clinicians, also among the least likely to be concerned with 
their own health, as other aspects of their lives are likely to become secondary to their 
addiction. Furthermore, the high prevalence of mental illness in this HIV infected 
population makes it difficult for patients to initiate and even more difficult to remain 
adherent to treatment, which is of vital importance to the effectiveness of ARV. Poverty 
is also rampant among this population.  Understandably, immediate concerns of housing 
and nourishment most often trump patient concerns of addressing potential HIV 
infection. In addition, the transient nature of this population makes it difficult to keep 
track of the locations of patients, further complicating the scheduling of follow-up visits 
with physicians and arranging pharmacies to dispense ARV. Initial access to health care 
can also be a challenge among Saskatchewan’s rural inhabitants. Another significant 
obstacle to the mitigation of the HIV epidemic in Saskatchewan is the unwillingness of at 
risk individuals to be tested for or seek treatment for HIV. Such attitudes are likely due to 
stigma surrounding HIV. Delayed testing and treatment of this disease ultimately leads to 
an increased number of individuals presenting to hospital with end stage AIDS. At this 
stage in disease progression prognosis is much poorer than if care had been sought at an 
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earlier stage, not to mentioned the substantial increased cost of treating an AIDS patient 
in hospital versus in an outpatient setting. The HIV epidemic in Saskatchewan is so 
severe that it has been suggested that it more closely resembles HIV epidemics in 
developing nations. 
 
2.6. Epidemiology of HIV in Saskatoon 
The city of Saskatoon is under the jurisdiction of the Saskatoon Health Region (SHR) 
and includes more than 73% of the total population serviced by the SHR (43). The SHR 
has a total population of 298,371, almost 29% of the entire province (44). According to 
the SHR Health Status Report 2008, the SHR has recorded the highest number of cases of 
HIV across all regional health authorities in Saskatchewan since 2005 (see Figure 1.8). It 
is noted that this finding most likely represents intensive HIV testing efforts; however, an 
increased occurrence of transmission is acknowledged in this report.  
Since 2004, more than 300 cases of HIV have been reported in the SHR. The majority 
(77%) have been among patients of self-reported First Nations, Métis or Inuit ethnicity. 
Consistent with provincial trends IDU is the most commonly reported exposure for HIV 
infection. Between 2004 and March 2007, 80% of cases reported IDU as an exposure and 
an additional 73% reported sex with an IDU as an exposure. MSM, the most commonly 
reported exposure on the national scale, was reported among only 7.3% of cases in the 
SHR in this same time interval (1). Also, in contrast with national trends, the proportion 
of reported female cases since 2004 were almost equal to male cases (1). Unprotected sex 
continues to pose a risk for HIV transmission as 34% of cases reported sex with a partner 
in whom HIV infection was either confirmed or suspected.  
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Figure 1.8. Incidence of HIV in SHR compared to incidence in Saskatchewan, 2004 – 2008.  
 
Source: Saskatoon Health Region 2008 Health Status Report (43). 
 
 
 
 
2.7. Risk Factors for Accelerated CD4+ Decline 
The following literature review will summarize the influence of the variables of 
interest in this thesis project on HIV disease progression. As CD4+ count is the outcome 
measure of this study, an emphasis will be placed on specifically describing ways in 
which factors of interest influence this marker of HIV disease progression. The breadth of 
research published on the effects of each of these factors on HIV is too vast to be covered 
completely in this literature review, therefore, we will attempt to summarize the 
consensus, where one exists, reached by the literature.  Additionally, it is important to 
consider that while each co-factor is presented separately in this literature review, in 
reality a single patient is very likely to possess multiple co-factors. Within that individual 
patient these multiple co-factors might cumulatively lead to a greater acceleration in 
CD4+ decline than could be accounted for by the additive effects of single co-factors.  
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2.7.1. Gender 
 Gender inequality is an important driver in the transmission of the global HIV 
epidemic. This social force is ultimately responsible for an increased risk of infection 
among women (45). At the root of this increased risk is a women’s lack of control over 
her body and life, especially in developing countries, where women’s rights and 
opportunities for education and self-empowerment may be dramatically lesser as 
compared to those of men (45). Gender inequality means that women are often not in a 
position to negotiate safe sex and therefore are at risk for infection by partners in HIV 
endemic populations (46).  
Pharmacokinetic, immunologic and genetic differences between men and women 
have the potential to exert differing influences on the clinical course of HIV (24). For 
instance, uninfected women are known to have higher CD4+ counts in the general 
population (27,47). Women have also consistently presented with higher CD4+ counts at 
seroconversion in cohort studies (47,48). However, whether this biological difference 
confers any advantage in terms of better prognosis among women is unclear. Reported 
effects of gender differences in rate of CD4+ decline among have been mixed. Where 
Lodi et al. (2011) and Mocroft et al. (2000) both recorded no differences in rate of CD4+ 
decline between genders, Anastos et al. (2000) reported a more rapid decline in CD4+ 
count among women. However, in Anastos et al.’s (2000) study the selection of male and 
female cohorts for comparison may be called into question. The female cohort comprised 
the Women’s Interagency HIV Study (WIHS) and the male cohort was the Multicenter 
AIDS Cohort Study (MACS) a cohort of homosexual men in the United States. Of 
concern were findings that women had lower CD4+ counts, were significantly older, were 
 27 
more likely to be black or Hispanic, to report IDU, and to have symptoms. Each of these 
factors found at increased prevalence among the female cohort chosen for this study has 
been independently associated with accelerated rates of CD4+ decline (see Sections 
corresponding to each of these cofactor in this literature review).  In addition, there was a 
temporal difference in the collection of data where data from the WIHS was collected 
from October 1994 to November 1995 and data from the MACS was collected between 
April 1985 and April 1987, which again may call into question the validity of conclusions 
drawn based on comparisons.  
Gender differences in immunological response to ARV has also been the subject of 
conflicting reports.  Giordano et. al. (2003) observed a greater mean CD4+ cell count 
increase among women as compared to men at 6 months following initiation of ARV 
(24), whereas, no difference in response to treatments were recorded among patients at a 
clinic in Southern Alberta (47).  
Implications of differences in response to ARV by gender for survival following 
initiation of ARV are also inconclusive. The study conducted at this Southern Alberta 
clinic noted a lower prevalence of AIDS among women at their first visit, however this 
was reportedly not cause for differences in prognoses between genders. A New York City 
study investigating causes of death among HIV-infected individuals in the post-HAART 
era found the mortality rate attributable to HIV-related causes to be higher among women 
(49). An analysis of data from a collaboration of 23 HIV seroconverter cohort studies in 
Europe, Australia and Canada concluded that overall women in developed countries 
survive longer following HIV seroconversion as compared to men in the post-HAART 
era (50). Prior to the widespread availability of ARV there was no significant differences 
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in risk of AIDS and death between men and women. Beginning in 1997 and ever since 
that time, women had a much lower risk of AIDS and death (50). It has been suggested 
that ARV, in lowering the risk of death from HIV, once again exposes the higher 
incidence of mortality among men in the general population (50). Differing risk 
behaviours present among study cohorts likely explain observed differences by gender in 
HIV prognosis following ARV initiation. Were underlying biological differences the 
cause of varying  prognoses among genders more consistent results would be expected 
across multiple study cohorts. 
 
2.7.2. Age 
Age is a well-established predictor of overall health status, with older individuals 
at increased risk for poorer health (49). Age also has prognostic value for HIV/AIDS 
outcomes. Older age is associated with an increased risk of accelerated progression to 
AIDS and death (13,47,49,51-54). Older age at the onset of treatment has also been 
associated with poorer survival (13,19,55). This association between more advanced age 
and the greater likelihood of adverse outcomes has been observed across groups 
including, men, women, IDU, MSM, and those infected by heterosexual sex (52,56). It 
has been postulated that faster progression among older individuals may occur because 
on average older individuals are more likely to be infected with a greater number of 
opportunistic infections that might become reactivated during severe immunodeficiency 
(51). 
The association of advancing age with accelerated decline in CD4+ count, as 
might explain the higher incidence of AIDS and death among older individuals, is less 
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clear. Where Phillips et. al. (1991) found no evidence of a more rapid rate of decline in 
CD4+ count among older patients, Lodi et. al. (2011) did find a significant influence of 
increasing age on accelerated CD4+ decline (48,51).  
 
2.7.3. Ethnicity 
 Socially and biologically produced conditions associated with ethnicity may 
produce worsened HIV prognoses among disadvantage groups. In developed countries, 
ethnic minorities are at a disproportionately high risk of acquiring HIV, and have not 
benefited as greatly from ARV as the general population (7). For example, findings from 
Louisiana show that African Americans were more likely to miss clinic visits, suggesting 
this ethnic group are not receiving early intervention services (57).  In a study conducted 
in New York City, HIV-related deaths were higher among people of black and Hispanic 
ethnicity as compared to people of other ethnicity (49). Ethnicity was also associated with 
length of survival following AIDS diagnosis in a study conducted in Philadelphia, with 
Whites as compared to non-Whites having a longer survival time even after controlling 
for income (58). Minority groups are also more likely to be of a younger age at time of 
diagnosis, for example in the United States when comparing Hispanic individuals with 
individuals of Caucasian ethnicity (24). 
Genetic differences between ethnicities may influence CD4+ cell counts, viral “set 
points” (the steady state viral load reached early in infection), clinical disease progression 
and survival (20,26,59,60). For example, heterozygosity in the human leukocyte antigen 
(HLA) is associated with delayed AIDS diagnosis, whereas homozygosity is associated 
with rapid progession and death and HLA haplotypes are known to vary by ethnicity 
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(61). In addition, HLA-B35 positivity has been associated with a significantly greater rate 
of progression to AIDS (61,62). HIV-1 coreceptors also differ by ethnicity. For instance 
the "32 CCR5 mutation  (a co-factor integral to the binding of the HIV viral envelope to 
the CD4+ cell) is more prevalent among Caucasian populations and less prevalent in 
African Americans (20,63) This genetic mutation is associated with slower rates of 
progression to AIDS (63). Greater than 70% of our study population self-identified as of 
First Nations or Métis ethnicity, therefore in the following section we will examine the 
unique challenges faced by this ethnic group in achieving optimal health following HIV 
diagnosis.  
 
2.7.4. First Nations, Métis and Inuit Ethnicity 
First Nations, Métis and Inuit peoples are more likely, relative to the general 
Canadian population, to be afflicted with the following co-morbidities: a record of 
incarceration, STI infection, co-infection with HCV, and housing insecurity (3,40). As 
will be examined in the subsequent sections of this literature review, each of these co-
factors has shown to have some association with an accelerated decline in CD4+ count or 
an accelerated progression to AIDS or death. The causes of the increased incidences of 
such co-morbidities among this population are socially produced. Furthermore, not 
unexpectedly this ethnic group is also confronted with lower accessibility to ARV and a 
poorer prognosis as compared to other infected individuals in the general Canadian 
population (40).  
The results of a study by Monette et al. (2011) highlight the social and economic 
disadvantage of First Nation, Métis and Inuit peoples infected with HIV living in Ontario. 
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They found that, in comparison to Caucasian participants, First Nations, Métis and Inuit 
participants were more likely to have achieved lower levels of education, to report an 
annual average income of less than $10,000 and to report harmful alcohol and non-
medicinal drug use. First Nations, Métis and Inuit participants in this same study were 
also generally younger, more likely to identify as female or transgender women and 
heterosexual, have a history of incarceration, have a history of homelessness and live in 
unstable housing (i.e. hotels, shelters, motels, streets, parks, or couch-surfing). Similar 
conclusions were drawn in an Alberta study where additionally it was seen that 
Aboriginal patients suffered higher rates of all cause and HIV related mortality, as well as 
poorer rates of adherence to ARV (64).  
 
2.7.5. Substance Abuse 
Substance abuse and addiction has been associated with HIV/AIDS since the 
beginning of the epidemic. In recent years, the role of IDU in the transmission of HIV has 
diminished significantly in much of the developed world, Canada included (4,65). In 
contrast, among Canada’s First Nations, Métis and Inuit peoples IDU is the category of 
exposure to which the greatest proportion of incident cases are attributed and this number 
continues to grow (4,64) 
Substance abusers and drug addicts are at a heightened risk for initially 
contracting the HIV virus. Drug and alcohol use can lead to impaired decision making 
causing individuals to be more likely to engage in risky behaviours such as unsafe sex 
with multiple partners and the sharing of needles or other drug paraphernalia (65,66). 
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Importantly, infection with HIV through IDU and subsequent continued use is associated 
with a heightened risk of AIDS and death (49,55,67,68).  
The physiological effects of illicit drugs may also have adverse effects on CD4+ 
count.  For example, there is evidence that regular cocaine use depresses CD4+ counts 
independent of the effects of regular cocaine use on ARV adherence and HIV viral load 
(69). Cocaine has been shown to impair early activation events during CD4+ cell 
stimulation potentially placing HIV-positive cocaine-abusers at heightened risk for 
opportunistic infections (70,71).  The recent use of crack cocaine has also been seen to 
delay entry into clinical care (72). Furthermore, continued drug use increases the 
likelihood of contracting additional strains of HIV, which again has the potential to 
accelerate progression of the disease as well as to necessitate the implementation of 
increasingly complex ARV regimes to prolong life.  
IDUs are less likely to be prescribed ARV and less likely to remain adherent to 
regimes once prescribed (50,52,64,68,73,74). Cohort studies in Europe, Australia and 
Canada have all found IDUs to spend smaller proportions of time on ARV as compared 
to individuals infected through heterosexual sex (50,52). IDUs are also less likely to have 
regular follow-up visits or are more likely to fail to attend scheduled visits than patients 
infected through other means (52,57). These observations are likely due to comordidities 
present among drug using populations including chronic liver disease and psychosocial 
issues, complicating patients’ abilities to comply with therapeutic regimes and clinic 
attendance (75). Interruptions in treatment regimes have adverse effects on HIV 
outcomes (64). Encouragingly the use of injection drugs has not been seen to have a 
significant effect on CD4+ count response to ARV (24). 
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2.7.6. HCV  
HCV is the most commonly reported blood-bourne pathogen in the SHR (43). 
While on a national scale a decreasing trend in the incidence of HCV has been 
documented since 1997, in the SHR incidence has not declined and remains significantly 
higher than the national average (43). A challenge to the treatment of active HCV is that 
the treatment regime takes a greater physical toll on the body than treatment of HIV, 
therefore completion of HCV treatment requires greater social stability than treatment of 
HIV (42). Consequently, few patients in our study population are recipients of HCV 
treatment.   
Co-infection with HCV among HIV infected IDUs is highly prevalent as both 
viruses are transmitted through multiperson use of injecting equipment (67,76-78). 
Transmission of HCV through the sharing of needles is 10 times more likely than 
transmission of HIV (5,66,79). In an international meta-analysis of HCV prevalence 
among IDUs the median HCV seroprevalence among HIV seropositive IDUs was 90% 
(80). Increased morbidity and mortality among HCV-HIV co-infected IDUs has been 
documented (81). As IDU is the most commonly reported exposure among newly 
diagnosed cases of HIV in Saskatchewan it is important to examine the effect of co-
infection with HCV on CD4+ cell decline in our study population. 
Thus far there does not appear to be any definitive consensus as to the effects of 
HCV on the clinical and immunological progression of HIV among co-infected cohorts. 
Multiple investigations among cohorts in developed countries have found no influence of 
HCV co-infection on the clinical progression of HIV (77,78,82-84). Neither has HCV 
seropositivity been associated with lower mean CD4+ counts or faster rates of decline in 
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CD4+ counts (77,78).  In contrast, some investigations found significantly slower rates of 
clinical progression among HCV-negative patients as compared to HCV-positive 
individuals, where clinical progression was defined as the occurrence of weight loss, a 
decrease in initial Karnofsky’s index, an AIDS-defining illness or death (14).  
Reports of the effects of HCV coinfection on CD4+ count recovery following the 
initiation of ARV have also been mixed. Where Greub et. al. (2000) observed an 
association between HCV and delayed CD4+ cell recovery following the initiation of 
ARV, Giordano (2003) et.al. found no significant influence of HCV seropositivity on rise 
of CD4+ count following ARV initiation. In past years, addressing the long-term effects 
of chronic HCV infection was largely ignored as an HIV-related death was far more 
likely to occur much sooner (14,77). The prolonging of life by effective ARV now brings 
such concerns to the forefront among co-infected populations (14,77). 
 
2.7.7. STIs 
Infection with an STI, in particular those that are ulcerative in nature such as syphilis 
or herpes simplex virus 2 (HSV2), is associated with an increased risk for the sexual 
transmission of HIV, through increasing host infectiousness and increasing the biological 
susceptibility of the person exposed to HIV (18,46,66,85). Likewise, HIV infected 
individuals are at an increased risk of contracting STIs due to the overlap in risk 
behaviours leading to the contraction of these infections (86,87).  
According to the Saskatoon Health Region Health Status Report 2008 rates of STI 
infections are increasing in the SHR, particularly in Saskatoon’s core neighborhoods 
(King George, Riversdale, Pleasant Hill, Westmount, Meadowgreen and Confederation 
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Suburban Centre) (43). This report cites rates of chlamydia double those of national rates, 
increasing rates of gonorrhea, and a re-emergence of syphilis since 2006. Of importance 
to the current study and to the planning of interventions to mitigate the HIV epidemic in 
Saskatchewan, is the ongoing reporting of new STI infections among individuals of 
known HIV seropositive status. For instance, in 2007 8 individuals with previously 
reported HIV had a new STI. 
      STI co-infection among HIV-positive patients has a negative impact on HIV clinical 
course and has been associated with an increased risk of rapid progression to AIDS 
(11,88). Co-infection with an STI provokes the activation of latently infected CD4+ cells 
as the immune system responds to the infectious organisms, causing an increase in 
plasma viral load and a corresponding decrease in CD4+ count (11,86,88-90). Syphilis, 
for example, has been associated with significant decreases in CD4+ count in MSM, 
particularly among men infected with secondary syphilis who were not recipients of ARV 
(86,89). Secondary syphilis is a more generalized form of disease that might lead to 
greater immune activation than primarily syphilis(86). Encouragingly, CD4+ count has 
been seen to recover after the successful treatment of syphilis (85,89).  
 
2.7.8. Incarceration 
 In each Canadian province and territory the representation of First Nations, Métis 
and Inuit adults in correctional services exceeds their representation in the general 
population (91). In 2008, this ethnic group was represented 77% of adult male and 90% 
of adult female offenders in Saskatchewan’s provincial correctional facilities (3). The 
incarceration rate in Saskatchewan during May of 2006 is presented in Figure 1.9. and 
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shows the dramatic overrepresentation of First Nations, Métis and Inuit people in prisons 
in this province. These statistics are highly relevant to the current study as previously 
stated, greater than 70% of this study population self-identifies as belonging to this ethic 
group.  
 
Figure 1.9. Incarceration rate in Saskatchewan on Census Day, May 16, 2006 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Statistics Canada. The incarceration of Aboriginal People in adult correctional services (91).  
 
 
The prevalence of HIV among Canada’s incarcerated population is greater than 
that of the general population (3). This is likely due to prison populations often being 
composed of individuals whose past behaviours have placed them at an increased risk of 
HIV infection, such as substance abuse and/or commercial sex work (92,93). Of 
particular relevance to the current study is the report that approximately one third of 
patients seen at the WSCC have a history of incarceration (42). Due to the high 
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prevalence of HIV among patients frequenting this clinic it is important to examine the 
hypothesized negative impact of such a stressful event on HIV disease progression.  
A study of incarcerated inmates found that after several months of imprisonment 
CD4+ cell count decline among HIV infected individuals was more rapid as compared to 
patients in an outpatient setting, among patients not taking ARVs (19). Such findings 
were attributed to the potential immunological impacts of the stressful living conditions 
in correctional facilities (19). 
Incarceration also poses a significant threat to ARV adherence, which has the 
potential to negatively impact CD4+ counts. In Canadian prisons, challenges in obtaining 
medications upon entry, during transfers, and upon release have been identified (94). The 
reported high prevalence of HIV-related discrimination present within correctional 
institutions, prompts HIV-infected inmates to obtain and take their medication discretely, 
posing further threat to adherence (94).  
 
2.7.9. Social Assistance and Social Support 
The HIV/AIDS epidemic is primarily an epidemic among impoverished and 
marginalized people. It is in the poorest countries, and among the poorer peoples of the 
richest countries of the world where the impact of this devastating epidemic is most 
profound (6,43,58). Therefore, a high prevalence of receipt of social assistance among 
this study population is expected. It is therefore not inappropriate to extrapolate this result 
to the conclusion that many HIV-infected individuals in Saskatoon are of low socio-
economic status (SES). SES is a well-known social determinant of health and the 
association of lower SES with worsening overall health is well established.  
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Low income has also been seen to be predictive of reduced length of survival 
following an AIDS diagnosis (58,75). Likewise, employment has been associated with 
improved survival (53).  In an Italian study, differences in reduced survival among 
individuals of lower as compared to higher income were more pronounced among women 
and drug users (75). Decline in SES as a function of HIV disease progression has also 
been documented in a study based on MACS, namely as a result of the loss of full-time 
employment (95). Such a finding maybe indicative of the existence of a feedback loop 
whereby advancing disease leads to an inability to work, leading to lowered SES, which 
then again feeds back to contribute to worsening disease progression.  
Another prevalent condition among our study population, which could be 
attributed to low SES is malnourishment. Whether this condition is attributable to 
insufficient income to support dietary needs, IDU, alcoholism, side effects of ARV or 
progression of HIV disease was not differentiated in this study (91). Regardless, it has 
been found that even moderate degrees of malnutrition can have adverse effects on 
outcomes in HIV-infected persons (11,96).  In a study conducted in Singapore, there was 
an association of low BMI with reduced CD4+ response following initiation of ARV, 
however this trend was not significant (96).  Malnutrition may impair immune 
reconstitution, prolonging the period during which patients remain at increased risk for 
opportunistic infection (96). Malnutrition may also have adverse effects on drug 
absorption as well as lower patient threshold for drug toxicity (96).   
Denial of HIV infection and its potentially fatal consequences as well as a fear of 
disclosure of HIV status is common (57). Stigma attached to HIV-infected persons, 
isolates individuals from their support structure and increases feelings of depression 
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which may ultimately result in a loss of social support (57). Lack of social support has 
been identified as a risk factor for faster decline in CD4+ count as decreased social 
support may compromise immune functioning (97,98). Finally, Lesermanet. al. (1999) 
were among the first to provide evidence to suggest that stressful life events have a 
measurable negative impact on disease progression among a cohort of HIV-infected men.  
 
2.7.10. Case Management 
Case Management is a relatively new program to be introduced to patients 
primarily cared for at the WSCC. Case managers aid their clients in accessing such 
services in their community as income assistance, home health care and emotional 
counseling in order to ameliorate the economic, social, physical, and emotional well-
being of HIV infected individuals (99,100). Case Management has been shown to 
increase rates of linkage to care in a randomized clinical trial among a primarily low-
income study population at four urban American centers (72). Additionally, case 
management has been shown to be effective in preventing patients from becoming 
unstably housed and decreasing unmet needs for supportive services (99).  
 
2.7.11. ARV 
 The advent of effective ARV has been a defining feature of the HIV epidemic in 
the developed world and is responsible for the evolution of the virus from a fatal disease 
to a chronic condition. Treatment of HIV began in the early 1990s with the availability of 
prophylaxis against common opportunistic infections and progressed to the introduction 
of protease inhibitors and highly active antiretroviral therapy (HAART) by the mid- 
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1990s (49). ARV controls viral replication within the host’s body, allowing for 
immunological recovery marked by a statistically significant increase in CD4+ cell count  
(8,19,67,96). Greater decrease in viral load following initiation of ARV has been 
consistently associated with a greater increase in CD4+ cell count (24). Therefore, ARV 
has resulted in a dramatic decrease in AIDS related morbidity and mortality (49,67).  
As previously mentioned, CD4+ cell count is used by physician as a marker of 
immune function in order to determine optimum timing for initiation of ARV (47). The 
likelihood of an increase in CD4+ count in response to ARV has been observed to be 
greater in patients with less severely depressed immune systems. Longitudinal cohort 
studies and randomized clinical trials have shown those who begin therapy at a CD4+ cell 
count between 200 and 350 have lower rates of AIDS-defining diseases and death 
(9,23,24,54). Therefore, the USA Panel of the International AIDS Society recommends 
initiation of therapy, in asymptomatic patients, before CD4+ count decreases to below 
350 /µL (9). The presence of other comorbidities and risk factors for HIV disease 
progression have been identified as to also merit consideration of initiation of ARV, these 
include, high viral load (> 100 000 copies/mL), rapid CD4+ cell count decline (>100/µL 
per year), hepatitis B or C virus coinfection, HIV-associated nephropathy (HIVAN) and 
risk factors for non-AIDS diseases, particularly cardiovascular disease (9).  Lower rates 
of non-HIV related mortality among HIV-infected populations has also been attributed to 
elevated CD4+ counts following initiation of ARV (49).  
Since the transformation of HIV from a fatal diagnosis to a manageable chronic 
condition the impact of treatment decisions are profound (9). As a chronic disease HIV 
infection requires continuous therapy, usually over many decades (9). The maintenance 
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of a CD4+ count above 500 may result in a normal life expectancy, through the 
prevention of irreversible immunological damage associated with prolonged immune 
activation (9,67).  Therefore, appropriate timing of initiation of ARV is important in 
HIV-infected patients in order to promote optimal outcomes. Furthermore, it then 
becomes crucial that physicians identify patients with rapid decline in CD4+ count as 
these patients may progress to a CD4+ count at which treatment should be initiated more 
quickly than physicians might otherwise expect. In the absence of the identification of 
patients with a rapid decline in CD4+ count physicians may miss the optimal occasion at 
which to initiate ARV to the detriment of the patient.  
ARV adherence is also crucial to optimal outcomes. Reduced adherence to ARV 
has been associated with younger age, unstable housing, low SES, lack of transportation, 
lack of childcare, mental illness, poor social support, presence of other severe illnesses 
and illicit drug use (101). These barriers to adherence as well as those associated with 
cofactors previously described in this literature review are highly prevalent in our study 
population. Lack of adherence to ARV, as well as initiation and/or discontinuation of 
therapy without consulting a clinician has been identified as an important barrier to 
achieving optimal health outcomes in our study population.  
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3. Methods 
 
3.1. Theoretical Perspective  
 Much scientific knowledge about HIV/AIDS has been shaped through the 
biomedical model (102). The biomedical model is based on the ideology of 
individualism, focusing exclusively on biological and individual-level factors to explain 
the risk of acquiring HIV infection and subsequently individual characteristics associated 
with disease progression and the development of AIDS (102). Research conducted using 
this methodology is primarily focused on the analysis of data collected on individuals 
with or at risk of AIDS, and rarely incorporates knowledge of the social context of 
individuals’ lives (102). Due to the clinical nature of this study and thus the focus on the 
individual patient and the emphasis on medical intervention to prolong and improve the 
lives of HIV infected individuals in this study, the biomedical models theoretical 
perspective is employed in most regards.  
 Contrasting the biomedical model of disease is the field of social epidemiology, 
shifting the focus from the individual to social conditions as drivers of infectious disease 
transmission and progression (103). Fee and Krieger (1993) emphasize the social 
production of HIV and raise questions “…about how the social relationships of class, 
race, and gender affect people’s working and living conditions and thereby influence 
their health status…” (102).  
 In this study, attempts to measure social production of conditions leading to 
increased rates of CD4+ decline are made. Through the inclusion of variables such as 
gender, ethnicity, receipt of social assistance, and record of incarceration this study 
 43 
evaluates the effects of individuals’ lives shaped by both their personal history and the 
social groups to which they belong on rates of CD4+ cell decline (102). However, the 
source of data for an accurate representation of the social conditions of individual lives is 
greatly challenged by the source from which data was collected in this study.   
 
3.2. Study Design 
This study is a retrospective cohort study of longitudinal data collected from a 
medical chart review. Medical charts of HIV positive patients at the Positive Living 
Program (PLP) and the West Side Community Clinic (WSCC) in Saskatoon, 
Saskatchewan, Canada were reviewed. 
 
3.3. Setting and Population 
The two clinics, which are the focus of this study, are both located in the city of 
Saskatoon. Saskatoon is Saskatchewan’s most populous urban center, with an estimated 
total population of 234, 200 as of December 31st, 2011 (104). The study population 
includes HIV-infected patients followed at the PLP at Royal University Hospital (RUH), 
the WSCC, and/ or at both sites, as some infectious disease physicians practice at both 
sites and thus might see a given patient at both sites. The vast majority of HIV positive 
patients in the SHR access HIV care through these sites. The WSCC first opened in 1975 
and was re-located to its current location in May 2010 in order to increase the 
accessibility of its services to patients (105). This is a primary health care clinic offering 
programs and services specific to the First Nations and Métis, and low-income inner city 
population of Saskatoon (105). In May 2010 through the HIV prevention strategy the 
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Saskatchewan Ministry of Health increased funding to this clinic by $250,000 per year 
for increased physician and support staff (105). The PLP at RUH exclusively treats adults 
and children infected with HCV and or HIV, residing in central and northern 
Saskatchewan (106).    
 
3.4. Operational and Ethics Approval 
This study was initially approved by the Biomedical Review Ethics Board at the 
University of Saskatchewan in summer 2011 (REB no. 2011 – 96). Two subsequent 
amendments were submitted to this review board. The first amendment, submitted in July 
2011 modified the storage of data collected from a password protected computer to a 
remote ‘datashare’, a remote server upon which stored data can only be accessed by 
research team members. Also modified in this first amendment was the manner in which 
relevant patient charts would be identified for data collection. It was decided that the 
administrative assistants of infectious disease physicians at RUH would pull relevant 
patient charts. The second amendment submitted in November 2011 was to allow for the 
collection of the ‘Case Management’ variable, as had been requested by staff at the 
WSCC. As data collection also occurred at the WSCC ethical approval was obtained 
from this organization. See Appendix 1 for copies of ethics certificates.  
 
3.5. Data Collection 
Data was previously input into the dataset used in the current study by two former 
students. One student collected data at the WSCC between May and July 2010 with the 
resulting dataset comprised of patients diagnosed between January 2007 and July 2010. 
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The second student collected data from the PLP between August and December 2010 
with the resulting data set incorporating patients diagnosed between 2005 and December 
2010. In the current study, patient data was collected at the PLP between August 2011 
and November 2011, and at WSCC between November 2011 and December 2011. 
Throughout all of these data collection periods data was entered directly into a 
standardized excel spreadsheet, ensuring the collection of the same variables. Data 
collection in the current study focused on updating this existing database to include 
information on patients diagnosed in 2003 and 2004, as well as the most recently 
diagnosed patients as of November 30th, 2011. Patient data abstracted from medical 
charts included information pertaining to demographics (age, gender, ethnicity), date of 
HIV diagnosis, date of clinical AIDS diagnosis, risk factors (IDU, MSM, etc.), clinical 
variables (past medical history, co-morbidities, seroconversion illness etc.), laboratory 
testing (CD4+ count, CD4+ percentage, viral load), smoking status and ARV therapy. In 
order to ensure the security of this data, at the daily conclusion of data collection the 
spreadsheet was uploaded to the ‘datashare’ set up by Information Technology Services 
at the University of Saskatchewan. Discrepancies between information pre-existing in the 
data set and additions made in the current study were rectified by updating the dataset to 
reflect the data available from the most recent physician’s note and/or lab results. Care 
was taken not to duplicate patient records kept at both clinic locations.  
Two forms in particular were important in obtaining baseline patient 
characteristics, The Saskatchewan Ministry of Health HIV Case Reporting Form and the 
Saskatoon Health Region HIV Initial Assessment. A physician or nurse in the presence of 
the patient upon the occurrence of a new HIV case completes these forms. The Public 
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Health Agency of Canada HIV/AIDS Case Report form was used when recording clinical 
AIDS diagnoses among patients.  
Regarding the collection of any variables involving dates, if only year was 
available date was recorded as January 1st and if only month was available the date was 
recorded as the 1st of the month. Smoking status, IDU, as well as other drug use was 
assessed as of the most recent physician’s note present in the medical chart of a given 
patient. The following section describes the collection of key variables. 
 
3.6. Variables 
 
Last negative HIV serology- This information, when available was collected from the 
HIV initial assessment form or from an HIV negative lab result if contained in the chart.  
 
Date of HIV diagnosis (day, month and year)- This information was recorded from the 
SHR HIV Initial Assessment Form, the Saskatchewan Ministry of Health HIV Case 
Report Form or directly from the lab report. Date of HIV diagnosis was recorded from 
results of the Western blot test. When discrepancies existed between physician’s notes 
and laboratory results, documented laboratory results were used to determine the date of 
HIV diagnosis.  
 
Gender- This variable was obtained from either the HIV Case Report or HIV Initial 
Assessment form, or other gender identifying information present in physicians notes or 
on lab results.  
 
Age at diagnosis- This variable was calculated by subtracting patient date of birth from 
the date of HIV diagnosis.  
 
Ethnicity- This variable was obtained from either the HIV Case Report or HIV Initial 
Assessment form. For several patient charts at the WSCC neither of these forms was 
available. In these instances SWITCH clinic (a student run clinic at WSCC) forms which 
detailed age, sex, ethnicity and neighborhood of patients was used to abstract this 
information.  
 
Hepatitic C Antibodies – Lab results pertaining to HCV testing were used to determine 
both HCV Ab and HCV PCR status. In addition, any information indicating HCV 
infection prior to HIV seropositivity was recorded.  
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Comorbidity information- Baseline comorbidities were abstracted from the Saskatoon 
Health Region HIV Initial Assessment form. Any and all subsequent comorbities were 
recorded from physician’s notes and/or results of relevant lab tests.   
 
History of IDU- Patients were recorded as having a history of IDU if there was any 
indication of past injection drug use contained in their charts, even if they did not identify 
IDU as a risk factor for transmission of HIV. Overall, this variable indicates both those 
that indicated IDU as a risk factor for their acquisition of HIV and those who did not but 
whom nonetheless had a history of IDU.  
 
Incarceration- Any indication of incarceration during follow-up and information 
regarding length of imprisonment when available, was recorded.  
 
Social Assistance- A patient was recorded as being a recipient of social assistance by the 
presence of supplemental social assistance forms to be completed by physicians in order 
to receive additional benefits. These additional benefits would be aimed at fulfilling 
needs associated with the debilitating nature of HIV, in terms of chronic fatigue or weight 
loss, or other chronic conditions, in their medical chart. Other information, for example, 
that contained in physician’s notes indicating that a patient was a recipient of social 
assistance, was also used to obtain information on this variable.  
 
Case Management- A list of case management clients was provided by the director of the 
WSCC. Case management is intensive social support from a social worker. In this 
program social workers visit individuals in their own homes and assist with such tasks as 
getting to court, opening a bank account, and transportation to doctor’s appointments. 
This program was implemented to improve HIV-infected individual’s abilities to attend 
medical appointments regularly and remain compliant with treatment regimes, given the 
chaotic lives of some HIV-infected individuals in Saskatoon. 
 
HIV Exposures- Risk factors for HIV transmission were recorded from either the HIV 
Case Report or HIV Initial Assessment form.  
 
VL, CD4+ Counts and CD4+ % - These variables as well as the date of each count was 
recorded from lab results kept in patient charts. Baseline viral load and CD4 count were 
recorded as the earliest value recorded in a patient chart within 6 months of HIV 
diagnosis. The limit of detection of plasma HIV viral load was less than 40 copies/ mL.  
 
Death (day, month, and year) –Information on the date and cause of death was obtained 
from the HIV/AIDS Case Report form required by PHAC or based on any other 
information in the chart (i.e., physician’s notes, newspaper obituary clipping).  
 
ARV therapy - Information on ARV medications was recorded from both pharmacy 
records and all pertinent physician notes. The medication name and the duration of the 
prescription was recorded. A completely accurate depiction of adherence to medication 
was not available from patient charts, however compliance was recorded as best was 
possible from these two sources of information.  
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3.7. Inclusion and Exclusion Criteria 
 
All HIV positive patients treated at PLP, WSCC, or at both sites were eligible for 
inclusion in this study. Patients must have been diagnosed HIV positive for the first time 
between January 1st, 2003 and November 30th, 2011. This time period includes the rapid 
increase in incident cases of HIV and was thus selected as the vast majority of patients 
treated at the PLP and the WSCC were diagnosed during these years. Thus this study 
represents the cohort of patients involved in the rise in new diagnoses in Saskatchewan, 
which is of most interest and understanding the characteristics of this population will be 
of the most importance in the mitigation of the HIV epidemic in Saskatchewan. 
Additionally, patients under 18 years of age were excluded from this study. Inclusion and 
exclusion criteria are summarized below. 
Inclusion criteria: 
(a) HIV positive patient treated at PLP, WSCC or both and diagnosed between 
January 1st, 2003 and November 30th, 2011 
Exclusion criteria 
(a) Under 18 years of age at time of diagnosis 
(b) HIV diagnosis prior to January 1st, 2003 or after November 30th, 2011. 
Based on exclusion criteria, a number of patients were removed from the final dataset. 
When both the Saskatchewan Ministry of Health HIV Case Reporting Form and the 
Saskatoon Health Region HIV Initial Assessment form were absent in the chart in 
addition to the absence of any other indication of the exact date of HIV diagnosis the 
patient was not included in the cohort. Twenty-two patients were removed due to an 
undocumented date of diagnosis. Thirty-three were removed due to having been 
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diagnosed with HIV earlier than 2003. Lastly, thirteen patients were excluded due to 
being aged less than 18 years at time of diagnosis. From an initial sample size of 525, 457 
patients remained in the data set. Figure 3.1 summarizes, this exclusion progress and the 
makeup of the final dataset.  
 
Figure 3.1. Summary of data set.  
 
 
 
IDU = 333 
No-IDU = 122 
(2 missing) 
HCV = 341 
No-HCV = 85 
(31 missing) 
Aboriginal= 279 
Non-Aboriginal= 114 
(64 missing)  
  
Women=212 
Men= 245 
(0 missing) 
All Patients  
N=525 
PLP Patients 
N = 244 (46.5%) 
 WSCC Patients 
N=169 (32.2 %) 
Both Sites  
N=112 (21.3 %) 
Study Data Set 
N= 457 
Diagnosed prior to 2003 N= 33 
 
Unknown date of diagnosis N = 22 
Less than 18 years of age at diagnosis N = 13 
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3.8. Variable Selection. 
Table 3.1 summarizes all independent variables collected and thereby available 
for use in analysis. However, not all variables were considered for inclusion in statistical 
analysis due in large part to missing information.  
HIV Diagnosis date was not used as data was collected retrospectively following 
HIV diagnosis. Therefore, because patients were not followed prospectively from before 
their HIV diagnosis we cannot accurately ascertain date of HIV infection. Many 
individuals in this study population were likely infected several years prior to the date of 
their HIV diagnosis. This led to inaccuracies in recording other variables as well such as 
the occurrence of a seroconversion illness.  
It was seen during data collection that some individuals were inconsistent in their 
methadone use, being on and off methadone for monthly or yearly intervals. In spite of a 
documented association of engagement in methadone therapy with increased adherence 
to ARV, this variable was not used as the extent of engagement in such therapy by an 
individual patient was unknown (73,107). As the duration and adherence to methadone 
therapy was unknown for most patients and such inconsistencies could not be accounted 
for in the analysis this variable was unusable.   
Residency was not used, as due to the transient nature of this population and the 
suspected proportion of individuals who regularly experience housing instability it may 
not offer an accurate representation of the neighbourhoods in which study participants 
reside. Laboratory tests for co-infections such as Hepatitis A, Hepatitis B (HBV), 
tuberculosis (TB), and varicella may indicate immunity due to immunization and not 
evidence of prior infections, therefore these variables were not considered. The 
 51 
proportion of patients with a positive Mantoux test was also difficult to ascertain as a 
limited number of patients returned to the clinic to have the results of the test read after it 
was planted.  
Active IDU was also very difficult to assess, as it may not have been recorded on 
a regular basis in physicians’ notes or a patient may not have been seen within 6 months 
prior to the reviewing of their chart, active IDU was defined as use of illicit injection 
drugs within 6 months of the most recent clinic appointment. Smoking status of both 
cigarettes and marijuana was also difficult to assess for similar reasons. Despite, an 
association of cytomegalovirus (CMV) seropositivity with more rapid development of 
AIDS, the prevalence of CMV antibodies was found to be so great that it would not have 
statistical accurate to include in the analysis (12). Likewise HLA B35 positivity has been 
associated with rapid progression of HIV, however this genotype occurred at a very low 
prevalence in this population that again it would not have been statistically appropriate to 
include it in the analysis (61,62). 
ARV adherence was recorded principally from the Pharmaceutical Information 
Program (PIP), a program created by the Saskatchewan provincial government to provide 
health care professionals with access to a patient’s medication records, if it was included 
in the chart (108). The PIP was supplemented by any physician’s notes referencing the 
initiation or termination or adherence to therapy. Although, it would have been clinically 
relevant to include adherence to ARV this variable was excluded in statistical analysis 
due to multiple initiations and discontinuations of various therapeutic regiments by 
patients as well as an unavailability of accurate assessment of adherence. In addition, the 
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ARV records of patients diagnosed in other provinces or countries were not always 
available, or the information that was provided was not adequate for analysis.  
 
Table 3.1. Variables available in database.  
Category Variable Description Type 
 
Demographics 
 
Gender 
 
Female, Male or Other 
 
Categorical 
 Age  At Diagnosis Continuous 
 Ethnicity Caucasian, First Nations, 
Métis, African, Asian, Inuit, 
Other 
Categorical 
 Primary Residence Indicated by first three 
alpha-numerics of postal 
code 
Categorical 
 Secondary Residence Indicated by first three 
alpha-numerics of postal 
code 
Categorical 
 Site of Care 
 
PLP, WSCC, or both Categorical 
 
HIV Diagnosis Data 
 
Genotype 
 
HIV Viral Clade 
 
Categorical 
 Symptoms at diagnosis Symptomatic At HIV testing Categorical 
 Seroconversion illness 
 
Experienced Yes or No Categorical 
 
HIV Risk Factors 
 
Sex with male,  
Sex with female, 
Heterosexual sex with IV drug 
user, 
Heterosexual sex with bisexual 
male, 
Heterosexual sex with 
transfusion recipient, 
Heterosexual sex with 
hemophiliac, 
Born in endemic country, if yes, 
which country, 
Heterosexual sex with person 
with HIV/AIDS (diagnosed or 
suspected),  
Injection non-prescription drug 
user, 
Received pooled Factor VII/IX 
concentrate,  
Recent transfusion, 
Occupational exposure,  
Other medical exposure, 
Other non-medical exposure 
(tattoo, acupuncture), 
Mother-to-child-transmission 
 
Category of HIV Exposure 
 
 
 
Categorical 
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Past Medical History Hospitalizations/ Admissions Yes or No, and reason for 
admission 
Categorical 
 Co-morbidities 
(i.e.malignancies, cardiac 
conditions, diabetes) 
List and date of diagnosis of 
condition 
Categorical 
 Family History List of medical conditions Categorical 
 
 
Infections 
 
 
Tuberculosis (TB) 
 
 
Date, Mantoux results, 
active TB, TB treatment 
 
 
Categorical 
 Result of HCV Antibody Tests Date, Positive or Negative Categorical 
 Results of HCV PCR Tests Date, Positive or Negative Categorical 
 HCV Genotype 1, 1a, 1b, 2b, or 3a Categorical 
 Cytomegalovirus (CMV) Ab Present or Absent  Categorical 
 Toxoplasma Ab Present or Absent  Categorical 
 Herpes simplex virus (HSV) Ab Present or Absent  Categorical 
 Varicella Ab Present or Absent  Categorical 
 Syphilis Ab Present or Absent  Categorical 
 Chlamydia Ab Present or Absent  Categorical 
 Gonorrhea Ab Present or Absent  Categorical 
 
Opportunistic/ Other 
Infections 
 
Pneumocystis Carinii 
Pneumonia (PCP) Date 
 
Date of diagnosis 
 
Continuous 
 Mycobacterium Avium 
Complex (MAC) Date 
Date of diagnosis Continuous 
 CMV Date Date of diagnosis Continuous 
 Oral Hairy Leukoplakia (OH) 
Date 
Date of diagnosis Continuous 
 Candida Date Date of diagnosis Continuous 
 Methicillin-Resistant 
Staphylococcus Aureus 
(MRSA)  
Yes or No, date of diagnosis 
(of available) 
Categorical 
 
Females only 
 
Pelvic Inflammatory Disease 
(PID) date 
 
Date of Diagnosis 
 
Continuous 
 Vaginitis Date Date of Diagnosis Continuous 
 Menstral History Regular, irregular, post-
menopausal 
Categorical 
 Last Pap Date, results Continuous 
 Contraception Type and frequency of use Categorical 
 Pregnancies Number of Pregnancies 
during course of HIV 
infection 
Categorical 
 
Social 
 
History of IDU 
 
Ever an IDU, or never IDU, 
Yes or No 
 
Categorical 
 History of Incarceration Incarcerated during follow-
up, Yes or No 
Categorical 
 History of Social Assistance Indication of receiving 
during follow-up, Yes or No 
Categorical 
 Case Management Client Yes or No Categorical 
 Smoking Status (cigarettes and 
tetrahydrocannabinol (THC)) 
Current, Former and Ex-
smoker 
Categorical 
 Methadone Treatment Current, Previous, Referred, 
Never 
Categorical 
 Substance Abuse List of illicit drugs used  
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ARV Treatment 
 
History of ARV 
 
Ever on ARV, Yes or No 
 
Categorical 
 ARV Initiation Date of ARV Initiation Continuous 
 ARV Termination Date of ARV Termination Continuous 
 ARV Adherence Information regarding 
adherence to ARV while 
prescribed 
 
 
Table 3.2 summarizes the independent variables that were considered in the statistical 
analysis for association with CD4+ count rate of decline. These variables were selected 
both due to evidence of potential influence on CD4+ count identified in the literature 
review and due to availability at appropriate accuracy and completeness in the dataset.  
 
Table 3.2. Variables considered for inclusion in statistical analysis.  
Category Variable Description Type 
 
Demographics 
 
Gender 
 
Female, Male or Other 
 
Categorical 
 Age  At Diagnosis Continuous 
 Ethnicity Caucasian, First 
Nations, Métis, African, 
Asian, Inuit, Other 
Categorical 
Medical History Result of HCV 
Antibody test 
Positive or Negative Categorical 
 History of STI Tested positive for an 
STI during follow-up, 
Yes or No 
Categorical 
Social History of IDU Ever an IDU, or never 
IDU, Yes or No 
Categorical 
 History of Incarceration Incarcerated during 
follow-up, Yes or No 
Categorical 
 History of Social 
Assistance 
Indication of receiving 
during follow-up, Yes or 
No 
Categorical 
 Case Management 
Client 
Yes or No Categorical 
ARV Treatment History of ARV Ever on ARV, Yes or 
No 
Categorical 
 ARV Initiation Date of ARV Initiation Continuous 
 
 
3.9. Dependent Variables  
 In the natural history of HIV disease progression CD4+ cells decrease in number 
as a function of time since HIV infection. Therefore an infected person’s CD4+ cell count 
can be used to monitor disease progression. 
 55 
A total of 2, 554 CD4+ count measurements were recorded among this cohort. 
Individual patients recorded various numbers of CD4+ counts dependent on the duration 
of HIV infection, stage of HIV progression and clinic visit attendance, among other 
factors. As the infectious disease physicians treated this cohort attempted to see patients 
at 3 months intervals we divided the follow-up period into 3 month intervals with time 
zero being the time of diagnosis. If a given patient had greater than 1 CD4+ count 
recorded in a given interval the mean of all CD4+ counts recorded in this interval was 
used in the analyses.  If a given patient did not have any CD4+ counts recorded in a given 
interval this was recorded as missing. In addressing the three study objectives we used 
CD4+ count as a continuous variable in Objectives 1 and 2 and as a dichotomous variable 
in Objective 3. Here we present more detail on the dependent variable in this study 
specific to each Study Objective. 
 
Study Objective 1: To estimate the overall average rate of CD4+ count depletion over 
the follow-up period; specifically the differences in rates among the following groups 
will be investigated: Age at diagnosis; Gender; Ethnicity; HCV co-infection; History of 
IDU; antiretroviral therapy (ARV); Incarceration during follow-up; Individuals engaged 
in case management services; Individuals receiving social assistance; Individuals infected 
with an STI.  
Dependent Variable: CD4+ counts of all patients with at least 3 recorded CD4+ counts, 
where this count is a continuous repeated measurement variable over the follow-up time.  
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Study Objective 2: To determine the effects of the clinical and social factors listed in 
objective 1 on CD4+ cell count changes.   
Dependent Variable: All CD4+ counts among all patients, again where this count is a 
continuous repeated measurement variable over the follow-up time.  
 
 Study Objective 3: To identify subjects showing  “rapid”- CD4+ cell count decline, and 
to determine clinical and social factors associated with this designation. Rapid decline 
will be defined by the slope of CD4+ count for each individual. 
Dependent Variable: The dependent variable for Objective 3 is dichotomous, rapid 
CD4+ cell count decline as compared to slow CD4+ count decline. Rapid decline was 
defined as the steepest 25% of slopes and slow decline as the shallowest 25% of slopes, 
as estimated from CD4+ counts of patients recorded while not these patients were not 
receiving ARV by both linear regression and mixed effects models analyses.  
 
 3.10. Statistical Analysis 
To investigate the study objectives the following statistical analyses were performed. P-
values were used to determine statistical significance. Time of HIV diagnosis is equal to 
month since diagnosis having a value of zero.  
Firstly, baseline patient characteristics were summarized by calculating the mean 
(SD) and of continuous variables and the frequency of count (%) variables using SAS 
codes PROC MEANS. Pearson chi-square tests were used to examine potential 
collinearity among cofactors using SAS code PROC FREQ.  
 57 
To examine the first study objective, a linear regression of CD4+ counts was fit 
for each patient with at least 3 recorded CD4+ counts using SAS code PROC REG. 
Subsequently, these individuals were assigned to groups based on gender, ethnicity, HCV 
co-infection, history of IDU, incarceration, recipient of social assistance, case 
management, STI co-infection, and receipt of ARV. Ethnicity was collapsed into the two 
categories of First Nations/ Métis and other, including Caucasian, African and other 
ethnicity. This was due to the low frequency of patients identifying as African or of other 
ethnicity. The mean slope among all individuals in each group was calculated and t-tests 
and Wilcoxon rank tests were performed using the SAS codes PROC TTEST and PROC 
NPARLWAY WILCOXON to assess statistically significant differences. Both t-tests and 
Wilcoxon rank tests were performed for comparison in the event that we made incorrect 
assumptions regarding the normality of the distribution of CD4+ count intercepts and 
slopes. The Wilcoxon rank test in a non-parametric test and thus does not assume any 
underlying distribution of the data, whereas the t-test assumes a normal distribution of the 
data. If the results of both of these tests are consistent we can be more confident that our 
observed results are closer to reflecting true differences and similarities among 
CD4+counts at time of diagnosis and CD4+ count slopes over the follow-up period. 
To examine the second study objective the data was modeled longitudinally by 
fitting random effects models using the SAS code PROC MIXED with random intercept 
and random slope. When we model the data with mixed effects models we model the 
dependence of CD4+count on the cofactors in the model as well as the autocorrelations 
among repeated CD4+ counts measured for a given patient. All patients who recorded at 
least 1 CD4+ count during the follow-up period were included in this analysis. Random 
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effects models calculate estimates of average linear marker trajectories over time, while 
accounting for correlations among repeated CD4+ measurements from the same subject 
(21). These models allow for estimation of the CD4+ count progression over time of 
individual patients as well as account for missing CD4+ count measurements in the 
dataset. A univariate model was fit for each variable of interest. In these models time was 
continuous and in units of months. Explanatory variables with a p-value of 0.25 or less 
were considered for potential inclusion in a multivariate model. Due to high rates of co 
linearity among ethnicity, HCV-co infection and a history of IDU three multivariate 
models were fit. In the final multivariate models baseline covariates, which were 
determined to be significant in the univariate anaylsis, were adjusted for by inclusion in 
the mixed effects model. In practice this was done by the addition of baseline covariates 
to the model statement in the proc mixed code in the SAS program. 
A summary of the statistical analysis performed in Study Objective 3 is presented 
in Figure 3.2. To examine the third and final study objective, rates of CD4+ count decline 
were calculated by means of both linear regression and mixed effects models. Included in 
this analysis were CD4+ counts of patients who were not prescribed ARV during the 
follow-up period, in addition to CD4+ counts recorded before initiation of ARV therapy 
of patients who did receive ARV during the follow-up period. Therefore, only CD4+ 
counts recorded while patients were ARV naïve were included in this analysis. The 
exclusion of CD4+ counts recorded after patients were prescribed ARV, allows for the 
examination of the natural rate of CD4+ decline. The intent to treat principle was used in 
this analysis and we did not account for the effects of stoppages, changes, or non-
adherence to treatment regimes.  
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Only patients with at least 3 CD4+ were included in the linear regression. The use 
of at least 3 CD4+ counts recorded prior to initiation of ARV has previously been used in 
other studies to estimate CD4+ slope (19,23,55). This analysis was further restricted to 
include only two subgroups of patients, those with a first recorded CD4+ count of above 
500 and above 350 cells/mm3 (20). The outcome in this analysis was dichotomized as 
rapid decline or slow decline. Patients were identified as having a rapid or a slow rate of 
CD4+ count decline by the quartile distribution of the slope of CD4+ count in both linear 
regression and mixed effects models. Patients with the steepest 25% of slopes were 
designated as having a rapid rate of decline and patients with the shallowest 25% of 
slopes were designated as having a slow rate of decline. 
A bivariate logistic regression analysis was performed for each of the variables of 
interest using SAS code PROC LOGISTIC. Variables with a p-value of less than 0.25 
were considered candidates for inclusion in multivariate models. Taking into account the 
high collinearity between ethnicity, HCV co-infection and IDU, multivariate logistic 
regression models were built to estimate the associations of relevant variables to patient 
designations of rapid and slow decline. Interaction terms comprised of First Nations or 
Métis Ethnicity with ARV; HCV with ARV; and IDU with ARV were included in 
multivariate models to assess for significance. 
The type I error rate was set at != 0.05. All analysis was done using SAS version 
9.2. 
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Figure 3.2. Summary of statistical analysis to examine Study Objective 3. 
 
 
 
 
 
 
 
 
 
 
Initial CD4+ count # 500 
cells/mm3 (subgroup 1) or 
 # 350 cells/mm3 (subgroup 2) 
Patients with at least 3 
CD4+ counts recorded 
while ARV naive 
Linear Regression 
Rapid rate of decline: 
25 % steepest slopes 
Slow rate of decline: 
25% shallowest slopes 
Mixed effects models 
Slow rate of decline: 
25% shallowest slopes 
Rapid rate of decline: 
25 % steepest slopes 
Bivariate Logistic 
Regression 
Multivariate Logistic 
Regression 
Bivariate Logistic 
Regression 
Multivariate Logistic 
Regression 
All CD4+ counts of 
patients recorded while 
ARV naive 
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4.Results 
 
4.1 Baseline Characteristics 
4.1.1. Demographics and Social Characteristics.  
Baseline patient characteristics are summarized in Table 4.1. A total of 457 HIV 
infected patients met the inclusion criteria for this study. The average age at HIV 
diagnosis was 35.6 (SD ± 10.1) years. There were 245 patients who identified as of male 
gender (53.6%). Information describing ethnicity was not available for 64 patients. 
Several patients’ ethnicity was designated as both Caucasian and Métis, in these instances 
individuals were categorized as Métis. Among those about whom information on 
ethnicity was available, 279 (71.0%) self-identified as First Nations (n=245, 62.3 %) or 
Métis (n= 34, 8.7%), and 114 (29.0 %) self-identified as being of other ethnicity. Within 
the group identifying as of other ethnicity, 94 (23.9 %) were Caucasian, 16 (4.1 %) were 
African, and 4 (1.0 %) were of other ethnicity. The most commonly reported HIV 
exposure category was IDU (n=324, 74.5%), followed by heterosexual contact (n=68, 
15.6%), MSM (n=29, 6.7%) and MSM/IDU (n=13, 3.0%). Three-hundred and thirty 
three (72.9%) patients had a history of IDU or reported IDU as an exposure. Two 
hundred and eleven (46.1%) patients attended clinic visits exclusively at the PLP, 143 
(31.3 %) exclusively at the WSCC, and 103 (22.5%) were seen at both sites. Among 212 
women, 41 (19.3%) experienced at least one pregnancy during the follow-up period, 34 
experienced 1 pregnancy and 7 experienced 2 pregnancies.  
One hundred and fifty-nine (34.8%) patients were recipients of social assistance 
and fifty-five (12.0 %) were case management clients. One hundred and thirty (28.4 %) 
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patients were incarcerated during the follow-up time. Information about smoking status 
was missing for 163 patients. Among those for whom information was available 33 
(11.2%) were non-smokers, 27 (9.18 %) were ex-smokers, and 234 (79.6 %) were current 
smokers.  
 
4.1.2. Clinical Characteristics 
Three hundred and fourteen patients (68.7%) were followed for at least 1 year. 
The mean follow-up time was 46.3 months (SD± 26.8). Four hundred and eleven patients 
had at least one recorded CD4+ count; the remaining 46 patients did not have any CD4+ 
counts recorded. Among these 411 participants, a total of 2,554 CD4+ counts were 
recorded. Two hundred and eighty three (61.9%) patients had a baseline viral load, 301 
(65.9%) patients had a baseline CD4+ count and 276 (60.4%) patients had both a baseline 
CD4+ count and a baseline viral load. In our study, the first CD4+ count and viral load 
recorded within 6 months of diagnosis was considered as the baseline measurement. 
Mean baseline CD4+ count was 378 (SD ± 233) cells/mm3 and mean baseline log viral 
load was 4.4 (SD ± 1.0) copies/mm3. The mean number of CD4+ counts recorded per 
patient during the follow-up period was 5.30 (SD ± 4.28) and the mean number recorded 
for a given patient in a single year was 2.3 (SD ±1.16). 
A total of 279 (61%) patients were recipients of ARV during the follow-up 
period. Three hundred and forty (74.4%) patients tested positive for HCV antibodies and 
278 (65.6%) had a positive HCV polymerase chain reaction (PCR), for 31 patients there 
was no record in their charts of HCV testing.  
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Thirty three (7.2%) patients were diagnosed with clinical AIDS and 192 (42.0%) 
patients were classified as having immunological AIDS (defined as having recorded at 
least one CD4+ count below 200 cells/mm3). In total, including both clinical and 
immunological AIDS diagnosis, 197 (43.1%) patients were diagnosed with AIDS during 
the study follow-up time. Thirty-three (7.2%) patients were deceased. The vital status of 
one patient was unknown.  
Table 4.1. Baseline patient characteristics (N=457). 
Variable Mean (± SD), Number (%)  
Mean Follow-Up Time (Months) 46.3  (± 26.8) 
Age (Years) 35.6 (± 10.14) 
Men 245 (53.6 %) 
Ethnicity 
Caucasian 
First Nations 
Métis 
African 
Other 
Missing 
 
94 (23.9 %) 
245 (62.3 %) 
34 (8.7 %) 
16 (4.1 %) 
4 (1.0 %) 
64 
First Nations or Métis 
Other 
279 (71.0 %) 
114 (29.0 %) 
Exposure category 
MSM 
MSM/IDU 
IDU 
Heterosexual contact 
Other 
Missing 
 
29 (6.7 %) 
13 (3.0 %) 
324 (74.5 %) 
68 (15.6 %) 
1 (0.2 %) 
22 
Total number of women who 
experienced pregnancy 
1 pregnancy  
2 pregnancies 
 
41 
34  
7 
Site 
PLP 
WSCC 
Both 
 
211 (46.1 %) 
143 (31.3 %) 
103 (22.5 %) 
Smoking Status 
Non-smoker 
Ex-smoker 
Current smoker 
Missing 
 
33 (11.2 %) 
27 (9.2 %) 
234 (79.6 %) 
163 
Case Management 55 (12.0 %) 
Social Assistance 159 (34.8 %) 
Case Management and Social 
Assistance 
29 (6.3 %) 
STI 142 (31.1 %) 
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ARV 279 (61.1 %) 
HCV antibodies  
Missing 
340 (74.4 %) 
31 
HCV PCR positive 278 (65.7 %) 
IDU 
Missing 
333 (72.9 %) 
2 
Incarcerated 130 (28.4 %) 
At least 1 CD4+ count 411 (89.9 %) 
Patients with baseline CD4+ count 301 (65.9 %) 
Baseline CD4+ count 377.7  (± 232.9) cells/mm3 
Mean Number of CD4+ counts per 
patient during follow-up period 
5.30 (± 4.28) 
Mean Number of CD4+ counts per 
patient in one year 
2.32 (± 1.16) 
Patients with a baseline viral load 283 (61.9 %) 
Baseline Viral Load 238,473 (± 957,189) copies/mm3 
Log 10 of baseline viral load 4.4 (± 0.96) copies/mm3 
Patients with both baseline viral 
load and baseline CD4+ count 
276 (60.4 %) 
Clinical AIDS 33 (7.2 %) 
Immunological AIDS  192 (42.0 %) 
Total AIDS   197 (43.1 %) 
All Cause Mortality 33 (7.2 %) 
 
 
4.2 Special Cases in Dataset 
Two patients were diagnosed with cancer during the follow-up time one with 
diffuse B cell lymphoma and the other with Hodgkin’s lymphoma. It was noted in these 
patients’ charts that low CD4+ cells counts recorded were more likely due to 
chemotherapy for the treatment of these malignancies as opposed to attributable to 
advancements in HIV disease progression. Another patient had an undetectable viral load 
despite not receiving any treatment and suspicion of advanced disease. It was noted in 
this patient’s chart that there maybe a mutation in the HIV virus prohibiting 
amplification. One patient, was recorded as never having received ARV in spite of being 
prescribed atripla, because this patient took this medication for only 2 days before 
discontinuing the medication due to side effects without consulting a clinician. This 
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patient was subsequently lost to follow-up for approximately two years, after which time 
ARV had not been reinitiated as of the completion of follow-up time for this study. 
Another condition causing depletion in CD4+ count unrelated to HIV disease 
progression is pregnancy (109). A total of 41 (19.3% of all women) women enrolled in 
this study experienced at least 1 pregnancy during the course of HIV infection, with 34 
women experiencing one pregnancy and 7 experiencing two pregnancies. Therefore, it is 
important to consider that any decline in CD4+ count observed during pregnancy might 
be naturally occurring and thereby unrelated to HIV progression. 
 
4.3 Association Analysis. 
Table 4.2 summarizes the association among selected variables. Pearson’s chi-
square tests were used to assess the associations between these categorical variables. The 
variables of HCV co-infection, First Nations or Métis Ethnicity and IDU are highly 
correlated.  Individuals with a history of IDU were 176.06 (p<0.0001) times as likely to 
also be HCV co-infected.  Individuals self-identifying as of First Nations or Métis 
ethnicity were 9.95 (p<0.0001) times as likely to have a history of IDU and 13.97 
(p<0.0001) as likely to be HCV co-infected. Also of note, the odds of HCV co-infection 
among Case Management Clients was 15.11 (p=0.0004) times that of patients not 
accessing such services and 11.43 (p<0.0001) times greater among patients with a history 
of incarceration. 
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Table 4.2. Chi-Square Test of selected variables with OR and 95% CI of OR and p-value.  
 
 
 
4.4. Overlap in Highly Associated Variables among the Study Population. 
 
Figure 4.1 summarizes the overlap of co-factors among the study population. This 
figure emphasizes the high degree of association among these three variables as was 
found in the association analysis (Table 4.2).  
 
 
 
 
 
 
OR 
95% CI of 
OR 
P-value 
Gender First 
Nations or 
Métis 
Ethnicity 
HCV co-
infection 
IDU Recipient 
of Social 
Assistance 
Case 
Manage-
ment 
Incar-
ceration 
Gender --- 0.26 
(0.16, 0.43) 
<0.0001 
0.57 
(0.35, 0.93) 
0.024 
0.53 
(0.35, 0.82) 
0.0040 
0.62  
(0.42, 0.91) 
0.0156 
0.23  
(0.12,0.44) 
<0.0001 
1.33  
(0.89, 2.01) 
0.17 
First Nations 
or Métis 
Ethnicity 
 --- 13.97 
(7.72, 25.28) 
<0.0001 
9.95 
(5.97, 16.58) 
<0.0001 
2.27 
(1.39, 3.69) 
0.0009 
5.43 
(1.91, 15.46) 
0.0005 
2.06 
(1.24, 3.44) 
0.0051 
HCV Co-
infection 
  
 
--- 176.06 
(65.87,470.54) 
<0.0001 
3.13  
(1.72, 5.69) 
0.0001 
15.11  
(2.06, 
110.96) 
0.0004 
11.43  
(4.09, 
31.94) 
<0.0001 
IDU    --- 2.61 
(1.59, 4.26) 
<0.0001 
7.34  
(2.25, 23.97) 
0.0001 
5.76  
(2.98, 
11.13) 
<0.0001 
Recipient of 
Social 
Assistance 
  
 
  --- 2.32  
(1.31, 4.09) 
0.0032 
1.25  
(0.82, 1.91) 
0.29 
Case 
Management 
     --- 1.10  
(0.60, 2.03) 
0.75 
Incarceration       --- 
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Figure 4.1.  Overlap of patient characteristics of First Nations or Métis Ethnicity, IDU and HCV co-
infection. (n= 457).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.5. Graphical Representations of Repeated CD4+ Count Measurements 
The CD4+ counts among 10 randomly selected patients are presented in Figure 
4.2. Figure 4.3. presents the mean CD4+ count among the entire population throughout 
the follow-up period. A series of Figures summarizing the mean CD4+ count in 3-month 
intervals, over the follow-up time among the total population and by variables of interest 
are presented in Figures 4.4 through 4.11. Table 4.3. summarizes the number of patients 
who contributed one CD4+ count to a given 3-month interval. In our study if more than 
one CD4+ count for a given patient was available during a single interval, the mean value 
of these counts was used. Graphs were truncated at 72 months due to the declining 
number of patients contributing CD4+ counts to the dataset after this many months of 
follow-up (see Table 4.3). 
Note: 56 patients 
did not possess 
any of these 
cofactors and 87 
patients had 
missing 
information 
regarding at least 
one of these 
cofactors 
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Figure 4.2. CD4+ counts recorded among 10 randomly selected patients.  
 
 
 
 
 
 
Table 4.3. Number of patients contributing at least 1 CD4+ count by 3-month intervals since time of diagnosis. 
Months "3 3-6 6-9 9-12 12-15 15-18 18-21 21-24 24-27 
Number 240 173 166 142 133 133 118 116 108 
Months 27-30 30-33 33-36 36-39 39-42 42-45 45-48 48-51 52-54 
Number 106 94 76 65 62 49 57 45 34 
Months 54-57 57-60 60-63 63-66 66-69 69-72 72-75 75-78 78-81 
Number 31 39 30 16 30 22 16 18 13 
Months 81-84 84-87 87-90 90-93 93-96 96-99 99-102 102-105 105-107 
Number 11 7 8 5 7 3 3 1 1 
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Figure 4.3. Mean CD4+ count with 95% confidence limits of the 3-month intervals over follow-up time.  
 
 
 
 
 
Figure 4.4. Mean CD4+ count in 3 months intervals over follow-up time by age at diagnosis, where error 
bars represent 95% confidence intervals. 
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Figure 4.5. Mean CD4+ count in 3 month intervals over follow-up time by gender with error bars 
representing the standard deviation,where error bars represent 95% confidence intervals. 
 
 
 
 
  
 
Figure 4.6. Mean CD4+ count in 3 month intervals over follow-up time by ethnicity, where error bars 
represent 95% confidence intervals. 
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Figure 4.7. Mean CD4+ count in 3 month intervals over follow-up time by HCV infection status, where 
error bars represent 95% confidence intervals.  
 
 
 
 
 
 
Figure 4.8. Mean CD4+ count in 3 month intervals over follow-up time IDU status, where error bars 
represent 95% confidence intervals. 
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Figure 4.9. Mean CD4+ count in 3 month intervals over follow-up time by receipt of social assistance, 
where error bars represent 95% confidence intervals. 
 
 
 
Figure 4.10. Mean CD4+ count in 3 month intervals over follow-up time among case management clients as 
compared to non-clients, where error bars represent 95% confidence intervals.  
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Figure 4.11. Mean CD4+ count in 3 month intervals over follow-up time among patients diagnosed with an 
STI during follow-up as compared to those who were not, where error bars represent 95% confidence 
intervals. 
 
 
 
 
Figure 4.12. Mean CD4+ count in 3 month intervals over follow-up time by incarceration during follow-up 
status, where error bars represent 95% confidence intervals. 
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Figure 4.13. Mean CD4+ count in 3 month intervals over follow-up time by receipt of ARV status (at any 
time during follow-up period) , where error bars represent 95% confidence intervals.  
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4.6. Objective 1: Results from Linear Regression Analysis 
 
4.6.1. Overall Rate of Change in CD4+ Count Determined by Univariate Linear 
Regression.  
 
 The mean rate of change in CD4+ count over the follow-up period was estimated 
using linear regression. In this analysis we included all patients with a minimum of 3-
recorded CD4+ counts. This resulted in a total of 284 (62.1%) patients meeting the 
inclusion criteria. The mean intercept among included patients was 370.5 (SE = ± 259.6) 
cells/mm3 and the mean slope was -0.67 (SE=±10.2) cells/mm3 per month.  
 
4.6.2. Study Objective 1: CD4+ Rate of Change Among Groups of Interest. 
 
In order to examine differences in rates of change in CD4+ count associated with 
cofactors of interest slope of CD4+ count was first estimated for each patient using linear 
regression. Subsequently, the mean slope among patients possessing a given cofactor was 
calculated and compared to the mean slope among patients in whom the same cofactor 
was absent. In order to examine older as compared to younger age at diagnosis patients 
were categorized as above or below the mean age at diagnosis (36 years of age). T-tests 
as well as non-parametric Wilcoxon Rank Tests were used to compare the mean CD4+ 
intercepts and mean slope between groups. The results of study objective 1 are 
summarized in Table 4.4. Equations generated by this analysis follow the formula: y = #0 
+ #1X1 + $.  
Where Y is the estimated CD4+ count at a given month since time of HIV 
diagnosis, #0 is the intercept (CD4+ count at months since diagnosis equal to zero, or at 
time of diagnosis) and #1 is the slope of CD4+ count in units of cells/mm3 per month 
since diagnosis.  
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Examples of the equations generated are given for the cofactors gender and 
ethnicity.  
T-tests were performed with results of Wilcoxon Rank Test in parentheses. Bolded p-values are significant 
at the 0.05 level. 
* Group difference in intercept 
** Group difference in slope 
Table 4.4. Estimates of CD4+ count intercept and slope as determined by univariate linear regression 
among patients with 3 or greater recorded counts (N=284).  
 
Variable 
 
 
Intercept (± SE) 
 
p-value* 
 
Slope (± SE) 
 
p-value ** 
Age 
$ 36 
 
> 36 
 
 
385 (280) 
 
351 (230) 
 
0.28 
(0.13) 
 
-1.53 (10.78) 
 
0.46 (9.40) 
 
0.10 
(0.059) 
Male 
 
Female 
355 (262) 
 
387 (257) 
0.53 
(0.47)  
-0.96 (11.41) 
 
-0.36 (8.82) 
0.62  
(0.89) 
First Nations or Métis Ethnicity 
Yes 
 
No 
 
371 (246) 
 
362 (241) 
 
0.78 
(0.92) 
 
-1.28 (10.65) 
 
0.35 (8.82) 
 
0.23  
(0.09) 
HCV 
Yes 
 
No 
 
380 (260) 
 
346 (256) 
 
0.36 
(0.60) 
 
-1.54 (11.07) 
 
2.37 (6.92) 
 
0.0079 
(0.0005) 
IDU 
Yes 
 
No 
 
389 (257) 
 
322 (265) 
 
0.058 
(0.075) 
 
-2.05 (10.56) 
 
3.03 (8.36) 
 
0.0002 
(<0.0001) 
Incarceration 
Yes 
 
No 
 
385 (269) 
 
364 (256) 
 
0.54 
(0.71) 
 
-3.26 (11.39) 
 
0.51 (9.47) 
 
0.06  
(0.02) 
Social Assistance 
Yes 
 
No 
 
353 (240) 
 
384 (272) 
 
0.33 
(0.30) 
 
-1.83 (10.90) 
 
0.051 (9.77) 
 
0.13 
(0.24) 
Case Management 
Yes 
 
No 
 
400.60 (272) 
 
364.78 (257) 
 
0.40 
(0.48) 
 
-1.27 (9.06) 
 
-0.56 (10.46) 
 
0.67 
(0.14) 
STI 
Yes 
 
No 
 
332 (229) 
 
391 (273) 
 
0.07 
(0.16) 
 
-0.26 (10.59) 
 
-0.90 (10.07) 
 
0.62 
(0.24) 
ARV 
Yes 
 
No 
 
307 (235) 
 
555 (239) 
 
<0.0001 
(<0.0001) 
 
0.58 (10.21) 
 
-4.30 (9.51) 
 
0.0004 
(<0.0001) 
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4.6.3. Gender 
 
Among patients of male gender the mean intercept was 355 cells/mm3 (SE= ± 
262) and the mean slope was -0.96 cells/mm3 per month (SE = ±11.4). Among patients of 
female gender the mean intercept was 387 cells/mm3 (SE ±257) and the mean slope was - 
0.36 cells/mm3 per month (SE ± 8.8).  
The equation for CD4+ count among men as estimated by linear regression analysis is as 
follows: 
CD4+ =  355 - 0.96 (month)  
 
Therefore, among men the estimated CD4+ at time of diagnosis is 355 cells/mm3 and 
CD4+ count is declining at a rate of -0.96 cells/mm3 per month.  
Among women the equation is: 
CD4+ =  387 - 0.36 (month) 
Therefore, among women the estimated CD4+ at time of diagnosis is 387 cells/mm3 and 
CD4+ count is declining at a rate of -0.36 cells/mm3 per month. Females have a higher 
mean CD4+ count at time of diagnosis, however this value is not significantly greater 
than that among males (p=0.31). Females in this population are experiencing a slower 
rate in CD4+ decline as compared to men, however this difference is not statistically 
significant (p=0.53).  
 
4.6.4. Ethnicity 
 Patients who self-identified as of First Nations or Métis ethnicity had a mean 
intercept of 371 (SE = ± 246) cells/mm3 and a mean slope of -1.28 (SE = ± 10.64) 
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cells/mm3 per month. The equation for CD4+ count as estimated by linear regression 
among patients of First Nations or Métis ethnicity is as follows: 
CD4+ = 371.03 - 1.28 (month)  
Patients who self-identified as of other ethnicity had a mean intercept of 362 
cells/mm3 (SE = ± 241) and a mean slope of 0.35 (SE = ± 8.8) cells/mm3 per month. The 
equation for CD4+ count as estimated by linear regression among patients of ethnicity 
other than First Nations or Métis is as follows: 
CD4+ =  361.7 + 0.35 (month)  
Patients of First Nations or Métis ethnicity had a higher CD4+ count at diagnosis 
and a steeper decline in CD4+ count. Neither CD4+ at time of diagnosis (p=0.78) nor 
CD4+ slope (p=0.23) was significantly different between these groups. 
 
4.6.5. HCV 
The mean intercept in patients among whom HCV antibodies were present was 
380 (SE = ± 260) cells/mm3 and the mean slope was -1.6 (SE = ± 11.1) cells/mm3 per 
month. The mean intercept among HCV negative patients was 346 (SE = ± 256) 
cells/mm3 and the mean slope was 2.4 (SE = ± 6.9) cells/mm3 per month. The mean 
intercept at time of diagnosis among HCV antibody positive patients was higher than 
among HCV un-infected patients, however this difference was not significant (p=0.36). 
The mean slope among patients in whom HCV antibodies were present was significantly 
steeper than among patients who were HCV antibody negative (p=0.0079).  
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4.6.6. IDU 
The mean intercept among patient with a history of IDU was 389 cells/mm3 (SE = 
± 257) and the mean slope was -2.1 (SE = ± 10.6) cells/mm3 per month. Among patients 
without a history of IDU the mean intercept was 322 (SD = ± 265) cells/mm3 and the 
mean slope was 3.0 (SE = ± 8.4) cells/mm3 per month. At time of diagnosis CD4+ count 
among patients with a history of IDU was higher than among patients without a history of 
IDU and this difference was very close to statistically significant (p=0.06). Patients with 
a history of IDU had a significantly steeper decline in CD4+ count as compared to those 
who had never been IDUs (p=0.0002).  
 
4.6.7. Incarceration 
 Patients who were incarcerated during follow-up had a mean intercept of 385 (SE 
= ± 269) cells/mm3 and a mean slope of -3.3 (SE = ± 11.4) cells/mm3 per month. Patients 
who were not incarcerated have a mean intercept of 364 (SE = ± 256) and a mean slope 
of 0.49 (SE = ± 9.5). Mean CD4+ count at time of diagnosis was higher among 
incarcerated patients, this difference was not significant (p=0.54). CD4+ count slope 
among individuals incarcerated during follow-up was almost significantly steeper than 
the slope among individuals not incarcerated during this time (p=0.06) and was 
significantly steeper when tested using the non-parametric Wilcoxon Rank Test (p = 
0.02).  
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4.6.8. Social Assistance and Social Support 
 Recipients of social assistance had a mean intercept of 353 (SE = ± 240) 
cells/mm3 and a mean slope of -1.9 (SE = ± 10.9) cells/mm3 per month. Patients without a 
history of receiving social assistance had a mean intercept of 383.5 (SD = ± 271) 
cells/mm3 and a mean slope of 0.05 (SE = ± 9.8) cells/mm3 per month. The mean CD4+ 
count at time of diagnosis was greater among patients who did not receive social 
assistance, this difference was not significant (p=0.33). The CD4+ count slope among 
recipients of social assistance was not significantly different as compared to that among 
patients who did not receive social assistance (p=0.13).  
 
4.6.9. Case Management 
The mean intercept among case management clients was 401 (SE = ± 272) 
cells/mm3 and the mean slope was -1.27 (SE = ± 9.1) cells/mm3 per month. The intercept 
among patients who were not case management clients was 365 (SE = ± 257) cells/mm3 
and the mean slope was -0.57 (SE = ± 10.5) cells/mm3 per month. The mean CD4+ count 
at time of diagnosis was higher among case management clients, however this difference 
was not significant (p=0.40). The mean slope was not significantly different between 
these two groups (p=0.67).  
 
4.6.10. STIs 
 The mean intercept among patients with a history of STI co-infection was 333 
(SE = ± 229) cells/mm3 and the mean slope was -0.29 (SE = ± 10.6) cells/mm3 per 
month. The mean intercept among patients without a history of STI co-infection was 391 
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(SE = ± 273) cells/mm3 and the mean slope was -0.90 (SE = ± 10.1) cells/mm3 per month. 
CD4+ count at time of diagnosis was greater among patients who had not contracted an 
STI and this difference neared statistical significance (p=0.07). The slope of CD4+ count 
was not significantly different between these two groups (p=0.62).  
 
4.6.11. ARV 
 The mean intercept among patients who received ARV was 307 (SE = ± 235) 
cells/mm3 and the mean slope was 0.57 (SE = ± 10.2) cells/mm3 per month. The mean 
intercept among patients who were not prescribed ARV during the follow-up period was 
555 (SE = ± 239) cells/mm3 and the mean slope was -4.3 (SE = ± 9.5) cells/mm3 per 
month. The mean CD4+ count at time of diagnosis among patients not receiving ARV 
during the follow-up period was significantly higher than patients who did receive ARV 
(p<0.0001). The mean slope among patients who were not prescribed ARV was 
significantly steeper than that among patients who were prescribed ARV (p=0.0004).  
 
4.6.12. Summary of Objective 1: Results from Univariate Linear Regression 
HCV co-infection, a history of IDU, a record of incarceration and not being 
prescribed ARV during the follow-up period were independently associated with negative 
slopes in CD4+ count, which were significantly steeper as compared to patients not 
characterized by such cofactors. Patients who were not prescribed ARV during the 
follow-up period had a significantly higher CD4+ count at diagnosis. There was no 
significant difference in CD4+ count at diagnosis, nor in CD4+ count slope among the 
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remaining cofactors of interest including, gender, ethnicity, receipt of social assistance, 
case management, or diagnosis with an STI during follow-up. 
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4.7. Objective 2: Results from Mixed Effects Analysis 
 
 In this study objective, mixed effects model were built to describe the effects of 
cofactors examined in Study Objective 1 on the CD4+ count of an individual patient.  
 
4.7.1. Results of Univariate Mixed Effects Analysis. 
The results of univariate analyses conducted for each variable of interest are 
summarized in Table 4.5. In these analyses we are making the assumption of a normal 
distribution of the dependent variable CD4+ count. The general form for equations 
generated by mixed effects models is:  
Yij= #0 + #1(group) + #2 (month) + #3 (group*month) +µ0 + µ1 (month) + $.  
Mixed effects models regression parameters have both population and individual level 
interpretations. Where yij represents the CD4+ cell count of the ith patient at the jth month, 
#0  represents the population mean intercept, #1 represents the group effect on the 
population and  #3 represents the interaction between the effect of a cofactor with time 
since diagnosis, again on the population mean. Individual effects are modeled by µ0 
representing random intercept and by µ1 representing the CD4+ count random slope, both 
for the ith patient. Examples of the equations generated by these mixed effects models are 
given for the variables of gender and age. In these examples we provide the population 
level interpretations of parameters in these equations. 
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Bolded p-values indicate group differences significant at the 0.05 level.  
 
 
Table 4.5. Univariate mixed effects models (n=411).  
 
Covariate  
 
 
Variable 
 
#  
 
95% CI (#) 
 
p-value 
Intercept 388 (354, 422) <0.0001 
Male -45.26 (-91.88, 1.36) 0.057 
Month -1.18 (-2.23, -0.14) 0.026 
Gender  
 
 
Male*Month 0.95 (-0.52, 2.43) 0.20 
Intercept 443 (360, 526) <0.0001 
Age at diagnosis  -2.85 (-4.43, 0.03) 0.053 
Month -2.85 (-5.45, -0.02) 0.032 
Age 
Age at diagnosis* Month 0.06 (-0.01, 0.13) 0.093 
Intercept 366 (323, 409) <0.0001 
First Nations  or Métis Ethnicity -9.20 (-60.85, 42.44) 0.73 
Month 0.39 (-1.87, -0.019) 0.56 
Ethnicity 
First Nations or Métis Ethnicity * Month -1.41 (-3.00,0.19) 0.084 
Intercept 355 (303, 407) <0.0001 
HCV  12.82 (-45.66, 71.31) 0.67 
Month 1.88 (0.47, 3.30) 0.0092 
HCV 
HCV*Month -3.36 (-5.00, -1.72) <0.0001 
Intercept 361 (316, 406) <0.0001 
IDU 7.82 (-44.78, 60.42) 0.77 
Month 1.14 (-0.18, 2.46) 0.092 
IDU 
IDU* Month -2.62 (-4.19, -1.05) 0.0011 
Intercept 367 (340, 395) <0.0001 
Incarceration -11.99 (-63.84,39.86) 0.65 
Month -0.27 (-1.15, 0.62) 0.56 
  
Incarceration
  
Incarceration*Month -1.24 (-2.83,0.35) 0.13 
Intercept 359 (334, 384) <0.0001 
Case Management  34.44 (-34.84, 103.73) 0.33 
Month -0.25 (-1.04, 0.54) 0.53 
Case 
Management 
Case Management * Month -2.68 (-4.68, -0.67) 0.0089 
Intercept 380 (351, 409) <0.0001 
Social Assistance - 42.70 (-90.93, 5.53) 0.083 
Month -0.46 (-1.39, 0.47) 0.33 
Social 
Assistance 
Social Assistance* Month -0.70 (-2.23, 0.82) 0.37 
Intercept 370 (341, 399) <0.0001 
STI -16.28 (-65.43, 32.87) 0.52 
Month -0.86 (-1.81, 0.09) 0.076 
 STI 
STI*Month 0.44 (-1.07, 1.96) 0.57 
Intercept 474 (437, 511) <0.0001 
ARV -169 (-215, -123) <0.0001 
Month -2.64 (-4.02, -1.26) 0.0002 
ARV 
ARV*Month 2.91 (1.29, 4.53) 0.0004 
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4.7.2. Gender 
The estimate of the univariate mixed effects model describing the effect of gender 
is presented in this section: 
CD4+ = 388 – 45.26 (gender) -1.18 (month) + 0.95 (gender*month)  
For example, females (gender =1) at month =2; 
CD4+ = 388 – 45.26 (1) -1.18 (2) + 0.95 (1*2)   
= 388 – 45.26 – 2.36 + 1.9 
=  344.64 cells/mm3 
Therefore, a patient of female gender at time 2 months after HIV diagnosis will have an 
estimated mean CD4+ count of 344.64 cells/mm3. 
For examples, males (gender = 2) at month = 2; 
CD4+ = 388 – 45.26 (2) -1.18 (2) + 0.95 (2*2) 
= 388 – 90.52 – 2.36 + 3.8 
= 298.92 cells/mm3 
Therefore, a patient of male gender at time 2 months after HIV diagnosis will have an 
estimated mean CD4+ count of 298.92 cells/mm3. Rate of CD4+ count change is not 
significantly different over time by gender (p=0.20). 
 
4.7.3. Age 
The univariate mixed effects model describing the effect of age at diagnosis on 
CD4+ status is presented in this section: 
CD4+ = 443 – 2.20 (age at diagnosis) -2.85 (month) + 0.06 (age at 
diagnosis*month)  
 86 
 
For example a patient aged 35 at diagnosis, at month = 2; 
CD4+ = 443 – 2.20 (35) -2.85 (2) + 0.06 (35*2)  
= 443 – 77 – 5.7 + 4.2 
= 364.5 cells/mm3 
Therefore, a patient 35 years of age at diagnosis at time 2 months after HIV diagnosis 
will have an estimated mean CD4+ count of 364.5 cells/mm3. Rate of CD4+ count change 
is not significantly different overtime with increasing age at diagnosis. 
 
A summary of the univariate mixed effects models including the remaining cofactors 
follows.  
 
4.7.4. Ethnicity 
CD4+ count among individuals self-identifying as First Nations or Métis was not 
significantly different as compared to individuals identifying as of other ethnicity 
(p=0.73). Time since diagnosis (in months) was not significant in this model (p=0.58), 
nor was the interaction term of time with First Nations or Métis ethnicity (p=0.084). 
 
4.7.5. HCV 
CD4+ count was not significantly different between HCV co-infected patients as 
compared to uninfected patients (p=0.67). Months since time of diagnosis was significant 
(p=0.0092) as was the interaction term between month and HCV co-infected (p<0.0001). 
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Therefore, rate of CD4+ decline was significantly more rapid among co-infected patients 
as compared to those who were uninfected.  
 
4.7.6. IDU 
CD4+ count was not significantly different when comparing patients with a 
history of IDU to those without such a history (p=0.77). Month since diagnosis was not 
significant in this model (p=0.092). The interaction term of IDU with month since 
diagnosis was significant (p=0.0011).  
 
4.7.7. Incarceration 
CD4+ count was not significantly different between patients who were 
incarcerated during follow-up up as compared to those who were not (p=0.65). Month 
since diagnosis also was not significant (p=0.56), nor was the interaction between 
incarceration and time since diagnosis (p=0.13). 
 
4.7.8. Case Management 
CD4+ count was not significant different between patients who were case 
management clients as compared to those who were not (p=0.33). Month since diagnosis 
was also not significant (p=0.53). However, the interaction term between case 
management and time since diagnosis was significant (p=0.0089). 
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4.7.9. Social Assistance 
CD4+ count was not significantly different between recipients of social assistance 
as compared to those who did not receive such social services (p=0.083). Month since 
diagnosis was not significant in predicting CD4+ count (p= 0.33), nor was the interaction 
between receipt of social assistance and time since diagnosis (p=0.37). 
 
4.7.10. STI 
There was no significant difference in CD4+ count between those diagnosed with 
an STI during follow-up as compared to those who were not diagnosed with such an 
infection (p=0.52). Time since diagnosis was not a significant predictor of CD4+ count in 
this model (p=0.076), nor was the interaction of STI infection with month since diagnosis 
(p=0.57).  
 
4.7.11. ARV 
ARV was a significant predictor of CD4+ count (p<0.0001). Time since diagnosis 
was a significant predictor of CD4+ count (p=0.0002). Receipt of ARV was associated 
with a positive CD4+ count slope, which was significantly different that the negative 
slope of CD4+ count among those who did not receive ARV at any time throughout the 
follow-up period (p=0.0004) 
 
4.7.12. Summary of Objective 2: Results from Univariate Mixed Effects Models.  
HCV co-infection, history of IDU, and case management were associated with a 
negative CD4+ slope and a significantly more rapid rate of decline in CD4+ count. 
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Receipt of ARV was associated with a positive CD4+ slope. Gender, age, ethnicity, 
incarceration, social assistance and STI co-infection were not significantly associated 
with CD4+ count, nor were there any significant interactions between these variables and 
month since diagnosis.  
 
4.7.13. Multivariate Analysis of Factors Associated with Trends in CD4+ count. 
Three separate mixed effects models were built due to the high degree of 
colinearity between First Nations and Métis ethnicity, HCV co-infection and IDU.  This 
is due to the fact that when one or more of the independent variables are correlated and 
these correlated variables are input together in the same model estimated regression 
coefficients can be highly unreliable.  
From the univariate mixed effects models analysis, gender, time since diagnosis, 
First Nations and Métis ethnicities, presence of HCV antibodies, history of IDU, 
incarceration, case management clients, recipients of social assistance, recipients of ARV 
and age at diagnosis, merit consideration for inclusion in the multivariate model based on 
a p-value of less than 0.25.  
 
4.7.14. Ethnicity (Model 1) 
The estimated mixed effects model including ethnicity was as follows:  
CD4+ = 617 - 145.16 (ARV) -2.23 (month) +– 46.36 (ethnicity) – 49.61 (social 
assistance) -3.01 (age at diagnosis) + 2.31 (ARV*month) 
CD4+ count increased at a rate of 2.31 cells/mm3 per month among recipients of ARV 
after controlling for other covariates. First Nations Ethnicity (p=0.029), receipt of social 
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assistance (p=0.0097) and age at diagnosis (p=0.0013) were also independent significant 
predictors of CD4+ count. Gender, a history of incarceration and being a case 
management client were not significant predictors and were therefore excluded from the 
model. The interaction between First Nations or Métis Ethnicity and ARV was tested and 
found not to be significant, therefore was also excluded. The AIC statistic for this model 
was 29683.8 . This model is summarized in Table 4.6.  
Table 4.6. Multivariate Mixed Effects Model containing First Nations or Métis Ethnicity 
(n=362). 
 
Cofactor 
 
#  
 
95% CI (#) 
 
p-value 
 
Intercept 
 
 
616 
 
(526.91, 706.15) 
 
<0.0001 
 
ARV 
 
 
-145 
 
(- 193, - 97.0) 
 
<0.0001 
 
Month 
 
 
- 2.23 
 
(- 3.70, - 0.76) 
 
0.013 
 
Month * ARV  
 
 
2.31 
 
(0.60, 4.01) 
 
0.0079 
 
First Nations or Métis Ethnicity 
 
 
- 46.36 
 
(- 88.01, -4.66) 
 
0.029 
 
Social Assistance 
 
 
- 49.63 
 
(- 87.20, -12.06) 
 
0.0097 
 
Age at diagnosis 
 
 
-3.01 
 
(-4.83, -1.18) 
 
0.0013 
 
4.7.15. HCV Co-infection (Model 2) 
 
The estimated mixed effects model including HCV co-infection was as follows:  
CD4+ = 606 -170 (ARV) -2.76 (month)– 65.73 (HCV) – 33.51 (social assistance) 
-1.83 (age at diagnosis) + 3.02 (ARV*month) 
CD4+ count increased at a rate of 3.02 cells/mm3 per month among recipients of ARV 
after controlling for other covariates. HCV antibody positivity (p=0.0046) and age at 
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diagnosis (p=0.042) were independently associated with lower CD4+ counts. Social 
assistance was forced into the model despite it having a p-value of less than 0.05, to allow 
for comparisons between the three models. Case management, a history of incarceration 
and gender were not significantly associated with CD4+ count and were therefore 
removed from the model. The interaction between receipt of ARV and HCV co-infected 
was tested and found not to be significant; therefore it also was not included in this 
model. The AIC statistic for this model was 30859.0 This model is summarized in Table 
4.7. 
 
 
 
Table 4.7. Multivariate Mixed Effects Model containing HCV co-infection (n=387). 
 
Cofactor 
 
 
#  
 
95% CI (#) 
 
p-value 
 
Intercept 
 
 
606 
 
(517, 695) 
 
<0.0001 
 
ARV 
 
 
-170 
 
(- 218, -122) 
 
<0.0001 
 
Month 
 
 
-2.76 
 
(- 4.17, -1.35) 
 
0.0032 
 
Month* ARV  
 
 
3.02 
 
(1.37, 4.67) 
 
0.0003 
 
HCV  
 
 
- 65.76 
 
(- 111.19, -20.33) 
 
0.0046 
 
Social Assistance  
 
 
- 33.51 
 
(- 71.48, 4.46) 
 
0.084 
 
Age at diagnosis 
 
 
-1.83 
 
(-3.59, -0.065) 
 
0.042 
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4.7.16. IDU (Model 3) 
 
The estimated mixed effects model including HCV co-infection was as follows:  
CD4+ = 590 -163 (ARV) -2.65 (month)– 41.67 (IDU) – 38.85 (social assistance) -
2.06 (age at diagnosis) + 2.76 (ARV*month) 
CD4+ count increased at a rate of 2.76 cells/mm3 per month among recipients of 
ARV after controlling for other covariates. A history of IDU (p=0.047), receipt of social 
assistance (p=0.0424) and increasing age at diagnosis (p=0.20) were independently 
associated with lower CD4+ counts. Case management, a history of incarceration and 
gender were not significantly associated with CD4+ count and were therefore removed 
from the model. The interaction between a history of IDU and receipt of ARV was tested 
and found not to be significant and was therefore also excluded from the final model. The 
AIC value for this model is 31615.2. The final model is summarized in Table 4.8. 
Table 4.8. Multivariate Mixed Effects Model containing history of IDU  (n=407). 
 
Cofactor 
 
#  
 
95% CI (#) 
 
p-value 
 
 
Intercept 
 
 
590 
 
(506, 673) 
 
<0.0001 
 
ARV  
 
 
- 163 
 
(-209, -117) 
 
<0.0001 
 
Month 
 
 
-2.65 
 
(- 4.03, -1.28) 
 
0.0022 
 
Month* ARV  
 
 
2.76 
 
(1.15, 4.38) 
 
0.0008 
 
IDU 
 
 
- 41.69 
 
(- 82.79, -0.59) 
 
0.047 
 
Social Assistance  
 
 
- 38.86 
 
(- 76.38, -1.34) 
 
0.042 
 
Age at diagnosis 
 
 
-2.06 
 
(- 3.79, - 0.32) 
 
0.020 
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4.7.17 Summary of Objective 2: Multivariate Mixed Effects Models 
 
 Common to all three models was the interaction between ARV and months. Age 
was also independently significant in all three models. Social assistance was independent 
significant in models 1 and 3 and marginally significant in model 2. Ethnicity, a history 
of IDU and HCV co-infection were each significant predictors of CD4+ count status in 
each of their respective models. Model 1 which included ethnicity had the lowest AIC.  
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4.8. Objective 3: Results from Logistic Regression Analysis 
 In this study objective we define rapid CD4+ decline in this population and 
subsequently identify cofactors associated with an increased risk of rapid decline. This 
analysis was undertaken amongst two subpopulations, patients with an initial CD4+ count 
of 500 cells/mm3 or greater and patients with an initial CD4+ count of 350 cells/mm3 or 
greater. Rapid decline was defined as the steepest 25% of CD4+ count slopes as estimated 
by both linear regression and mixed effects models among these two sub populations. 
Slow decline was defined as the shallowest 25% of CD4+ count slopes among these two 
subpopulations, again as estimated by both linear regression and mixed effects models.  
 
4.8.1. Results of Bivariate Logistic Regression Models Among Subgroup of Patients 
with First CD4+ Count %  500 cells/mm3 
 
4.8.2. Linear Regression 
Among patients with an initial CD4+ count greater than or equal to 500 cells/mm3 
with at least 3 recorded CD4+ counts while not receiving ARV, rapid decline was defined 
as a slope, as determined by linear regression analysis, of $ -12.58 cells/mm3 per month 
and slow decline was defined by a slope of # - 2.19 cells/mm3 per month. By these 
definitions 16 patients were identified as having rapid CD4+ cell count decline and 16 
patients were identified as having slow decline. A total of 32 patients were included in 
this analysis. The results of this analysis are summarized in Table 4.9. 
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Table 4.9. Bivariate logistic regression analysis of variables of interest among patients with first 
CD4+ count ! 500 cells where slope was estimated with linear regression (n=32). 
 
Covariates 
 
 
OR* 
 
95% CI** 
 
p-value 
 
Gender 
 
 
2.83 
 
(0.67, 12.02) 
 
0.16 
 
Age 
 
 
0.98 
 
(0.92, 1.04) 
 
0.54 
 
First Nations or Métis Ethnicity 
 
1.07 
 
(0.23, 5.02) 
 
0.93 
 
HCV 
 
3.50 
 
 
(0.56, 21.81) 
 
0.18 
 
IDU 
 
 
4.20 
 
(0.70, 25.26) 
 
0.12 
 
Case Management 
 
 
1.00 
 
(0.12, 8.13) 
 
0.99 
 
Social Assistance 
 
 
7.00 
 
(1.19, 41.36) 
 
0.03 
 
Incarceration 
 
4.33 
 
(0.88, 21.31) 
 
0.07 
 
STI 
 
 
0.51 
 
(0.10, 2.62) 
 
0.42 
 
ARV 
 
 
5.57 
 
(1.13, 27.52) 
 
0.04 
* OR = Odds Ratio 
**CI= Confidence Interval 
  
4.8.3. Gender 
 The bivariate analysis for the cofactor of gender is presented here: 
Y = 1 if rapid CD4+ count decline 
Y = 0 if slow CD4+ count decline 
Logit (Y) = #0 + #gendergender + $  
= -0.45+ 1.040 (gender) 
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Odd Ratio (OR) = Exp (#) = e1.040 = 2.83 
 
95% CI for e# = exp [#±1.96 (S.E.#)] 
 
95% CI for e#= exp [1.040±1.96 (0.74)] = (e-0.41, e 2.49) = (0.67, 12.02) 
 
In this example female gender is the reference category. Therefore, we interpret this OR 
as the risk of rapid CD4+ decline is 2.83 times greater among males as compared to 
females. This result is not significant as the 95% CI includes the value of 1.  
 
4.8.4. Age 
An increase in age at diagnosis by one year resulted in an individual being 0.98 as 
likely to be designated as having rapid decline in CD4+ count, this OR was not significant 
(p=0.54). 
 
4.8.5. Ethnicity 
Patients of First Nations or Métis ethnicity were 1.07 times as likely to be 
designated as having rapid decline in CD4+ count, which was not significant (p=0.93).  
 
4.8.6. HCV 
Patients who were HCV co-infected were 3.50 as likely to be identified as having 
rapid decline in CD4+ count, this was not significant (p=0.18).  
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4.8.7. IDU 
Patients with a history of IDU were 4.20 times more likely to be identified as 
having rapid decline in CD4+ count, this was not significant (p=0.12). 
 
4.8.8. Case Management  
Case Management clients were no more likely to be identified as having rapid 
decline in CD4+ count as compared to non-clients (OR = 1.00, p=0.999). 
 
4.8.9. Social Assistance 
Recipients of Social Assistance were 7.00 times as likely to be designated as 
having rapid decline in CD4+ count as compared to patients who never received social 
assistance and this was a significant difference between the groups (p=0.032).  
 
4.8.10. Incarceration 
Patients who were incarcerated during follow-up were 4.33 times as likely to be 
designated as having rapid decline in CD4+ count as compared to patients who were not 
incarcerated during this period. This result was not significant (p=0.071).  
 
4.8.11. STIs 
Patients infected with an STI during follow-up were 0.51 times as likely to be 
designated as having rapid decline as compared to those who were uninfected. This result 
was not significant (p=0.42).  
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4.8.12. ARV 
Patients who were prescribed ARV over the course of follow were 5.57 times 
more likely to be identified as having a rapid decline in CD4+ count as compared to 
patients who were not prescribed ARV in this same period. This result was significant 
(p=0.035). 
 
4.8.13. Summary of Bivariate Analysis among Patients with First CD4+ Count ! 500 
cells/mm3, where Slope was Estimated using Linear Regression 
 Receipt of social assistance and ARV were each significantly associated with an 
increased risk of rapid CD4+ cell count decline. Gender, age, ethnicity, HCV co-
infection, history of IDU, case management, incarceration and STI infection did not 
significantly increase the risk of such a designation among patients.  
 
4.8.14. Multivariate Analysis among Patients with First CD4+ Count ! 500 
cells/mm3, where Slope was Estimated using Linear Regression 
In the bivariate analyses among patients with an initial CD4+  count of 500 cells 
or greater, with at least 3 CD4+ counts recorded while not receiving ARV and where 
CD4+  rate of change was determined by linear regression, gender, HCV co-infection, a 
history of IDU, receipt of social assistance, a history of incarceration and receipt of ARV 
will be considered candidates for inclusion in the multivariate model based on a p-value 
of less than 0.25.  
In no constructed multivariate model did more than one covariate remain an 
independent significant predictor of an increased likelihood of designation with a rapid 
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CD4+ count decline. The models including the covariates which most closely approached 
significance are summarized in Table 4.10.  
 
Table 4.10 Multivariate logistic regression model among patients with an initial CD4+ % 500, where 
slope was estimated using linear regression (n=32). 
  
Covariates  
 
 
OR* 
 
95% CI** 
 
p-value 
 
IDU 
 
ARV 
 
 
5.82 
 
7.06 
 
(0.74, 45.65) 
 
(1.19, 42.02) 
 
0.094 
 
0.032 
 
Rapid decline  $ -12.58 cells/mm3 
per month 
 
Slow decline # -2.19 cells/mm3 per 
month 
 
 
HCV 
 
ARV 
 
 
5.16 
 
6.64 
 
(0.63, 42.33) 
 
(1.12, 39.51) 
 
0.13 
 
0.037 
*OR= Odds Ratio 
** CI=confidence interval 
 
The model containing IDU and ARV resulted in the most significant terms and is 
further examined here.  
Y = 1 if rapid CD4+ count decline 
Y = 0 if slow CD4+ count decline 
Logit (Y) = #0 + #IDUIDU + #ARVARV 
= -2.05 + 1.76 (IDU) + 1.95 (ARV) 
 
OR for IDU 
OR = e1.76 = 5.82  
95% CI for e# = exp [#±1.96 (S.E.#)] = exp [1.76 ± 1.96 (1.05)] = (e
-0.30 , e 3.82) = 
(0.74, 45.65)  
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OR for ARV 
OR = e1.95 = 7.06 
95% CI for e# = exp [#±1.96 (S.E.#)] = exp [1.95 ± 1.96 (0.91)] = (e 
0.17, e 3.74) = 
(1.19, 42.02) 
 
In this model patients with a history of IDU are 5.82 times more likely to experience 
rapid decline in CD4+ count. The 95% CI of this OR includes the value of 1 suggesting 
that history of IDU is not significantly influencing the risk of such a classification. 
Receipt of ARV is associated with 7.06 times greater odds of experiencing a rapid 
decline in CD4+ count. The 95% CI of this OR does not include the value of 1, indicating 
that this association is statistically significant.   
 
4.8.15. Mixed Effects 
When using a mixed effects model to determine CD4+ slope and among patients 
with an initial CD4+ count of 500 or greater recorded while not receiving ARV, rapid 
decline was defined as a slope of $ -3.33 cells/mm3 per month and slow decline as # 2.80 
cells/mm3 per month. A total of 50 patients were included in this analysis, 25 with a rapid 
decline and 25 with a slow decline. The results of this analysis are summarized in Table 
4.11.  
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OR = Odds Ratio 
** CI=confidence interval 
 
4.8.16. Gender  
There is no difference in the likelihood of being classified as having a rapid CD4+ 
decline between genders (OR = 1.00, p = 0.99).  
 
4.8.17. Age 
Y = 1 if rapid CD4+ count decline 
Table 4.11. Bivariate logistic regression analysis of variables of interest among patients with first 
CD4+ count ! 500 cells, where slope was estimated using mixed effects models (n=50). 
 
Covariates 
 
 
OR* 
 
95% CI** 
 
p-value 
 
Gender 
 
 
1.00 
 
(0.33, 3.03) 
 
0.99 
 
Age 
 
 
0.99 
 
(0.94, 1.04) 
 
0.56 
 
First Nations or Métis 
Ethnicity 
 
 
1.62 
 
(0.45, 5.78) 
 
0.46 
 
HCV 
 
3.83 
 
(0.69, 21.30) 
 
0.12 
 
IDU 
 
 
2.85 
 
(0.64, 12.64) 
 
0.17 
 
Case Management 
 
 
0.55 
 
(0.12, 2.58) 
 
0.44 
 
Social Assistance 
 
 
2.14 
 
(0.60, 7.68) 
 
0.24 
 
Incarceration 
 
2.67 
 
(0.75, 9.45) 
 
0.13 
 
STI 
 
 
1.96 
 
(0.62, 6.19) 
 
0.25 
 
ARV 
 
 
6.00 
 
(1.69, 21.26) 
 
0.01 
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Y = 0 if slow CD4+ count decline 
Logit (Y) = #0 +#age age  
= 0.52 -0.0152(age) 
OR = e-0.0152 = 0.99 
95% CI for e# = exp [#±1.96 (S.E.#)]  
95% CI for e#= exp [-0.015 ±1.96 (0.026)] = (e-0.066, e0.036) = (0.94, 1.036) 
Therefore, this OR is interpreted as for each 1 year increase in age at diagnosis a patient 
is 0.985 times as likely to be designated as having a rapid decline in CD4+ count. As the 
95% CI of this OR contains the value of 1 this OR is not significant.  
 
4.8.18. Ethnicity 
Patients of First Nations or Métis ethnicity were 1.62 times as likely to be 
designated as having a rapid decline in CD4+ count as compared to patients of other 
ethnicity. This result was not significant (p=0.46).  
 
4.8.19 HCV 
Patients who were HCV co-infected were 3.83 times as likely to be designated as 
having a rapid decline in CD4+ count as compared to uninfected patients. This result was 
not significant (p=0.12). 
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4.8.20. IDU  
Patients with a history of IDU were 2.85 times as likely to be designated as 
having a rapid decline in CD4+ count as compared to patients without such a history. This 
result was not significant (p=0.17). 
 
4.8.21. Case Management 
Case Management clients were 0.55 times as likely to be designated as having a 
rapid decline in CD4+ count as compared to non-clients. This result was not significant 
(p=0.44).  
 
4.8.22. Social Assistance  
Recipients of social assistance were 2.14 times as likely to be designated as 
having a rapid decline in CD4+ count as compared to patients who did not receive such 
funds. This result was not significant (p=0.24). 
 
4.8.23. Incarceration 
Patients who were incarcerated during follow-up were 2.67 times as likely to be 
designated as having a rapid decline in CD4+ count as compared to patients who were not 
incarcerated during this period. This result was not significant (p=0.13).  
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4.8.24. STIs 
Patients who were diagnosed with an STI during follow-up were 1.96 times as 
likely to be designated as having a rapid decline in CD4+ count as compared to those who 
remained uninfected. This result was not significant (p=0.25). 
 
4.8.25 ARV 
Patients who were prescribed ARV during the follow-up period were 6.00 times 
as likely to be designated as having a rapid CD4+ count decline as compared to patients 
who were not prescribed ARV in this same time period. This result was significant 
(p=0.0055).  
 
4.8.26. Summary of Bivariate Analysis among Patients with First CD4+ Count ! 500 
cells/mm3, where Slope was Estimated using Mixed Effects 
 In this bivariate analysis of covariates of interest only receipt of ARV was 
significantly associated with an increased risk of rapid CD4+ count decline. Gender, age 
at diagnosis, ethnicity, HCV co-infection, history of IDU, case management, receipt of 
social assistance, incarceration and co-infection with an STI were not significantly 
associated with an increased likelihood of this outcome.  
 
4.8.27. Multivariate Analysis among Patients with First CD4+ Count ! 500 
cells/mm3, where Slope was Estimated using Mixed Effects Models. 
In the bivariate analyses among patients with an initial CD4+ count of 500 cells or 
greater using CD4+ counts recorded before ARV was prescribed to define CD4+ slope 
 105 
with a mixed effects model HCV co-infection, history of IDU, receipt of social 
assistance, history of incarceration and receipt of ARV are eligible for inclusion in the 
multivariate model based on a p-value of less than 0.25.  
As previously mentioned in none of the constructed multivariate model was more 
than 1 variable independently significantly associated with a higher or lower likelihood of 
rapid or slow rate of CD4+ decline. The models including the covariates which most 
closely approached significance are summarized in Table 4.12.  
 
*OR = Odds Ratio 
**CI= confidence interval 
 
 
The model including HCV and ARV most closely approached significance and is 
further investigated here.  
Y = 1 if rapid CD4+ count decline 
Y = 0 if slow CD4+ count decline 
Logit (Y) = #0 + #HCVHCV + #ARVARV 
= -1.98 + 1.53 (HCV) + 1.83 (ARV) 
OR for HCV 
OR = e1.53 = 4.64 
Table 4.12. Multivariate logistic regression model among patients with an initial CD4+ % 500, where 
slope was estimated using mixed effects models (n=50). 
  
Covariates 
 
 
OR* 
 
95% CI**  
 
p-value 
 
IDU 
 
ARV 
 
 
3.62 
 
6.70 
 
(0.68, 19.27) 
 
(1.77, 25.36) 
 
0.13 
 
0.01 
 
Rapid decline $ - 3.33 cells/mm3 per 
month 
 
Slow decline  # 2.80 cells/mm3 per 
month 
 
 
HCV 
 
ARV 
 
 
4.64 
 
6.24 
 
(0.70, 30.74) 
 
(1.64, 23.74) 
 
0.11 
 
0.0072 
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95% CI for e# = exp [#±1.96 (S.E.#)] = exp [1.53 ± 1.96 (0.96)] = (e
-0.35 , e 3.41) = 
(0.70, 30.74) 
 
OR for ARV 
OR = e1.83 = 6.24 
95% CI for e# = exp [#±1.96 (S.E.#)] = exp [1.83 ± 1.96 (0.68)] = (e
-0.50 , e 3.16) = 
(1.64, 23.74) 
 
 In this model HCV co-infected patients were 4.64 times more likely to experience rapid 
CD4+ count decline. However co-infection with HCV did not significantly influence 
rapid CD4+ count decline as the value of 1 was present in the CI for this OR. Patients 
who were prescribed ARV were 6.24 times more likely to experience rapid CD4+ cell 
count decline. This result was significant as the value of 1 was not included in the CI of 
this OR.  
 
4.8.28. Summary of Results of Logistic Regression among Patients with Initial CD4+ 
Count ! 500 cells/mm3 
 
 In the bivariate logistic analysis among this sub population where slope was 
estimated using linear regression receipt of social assistance and ARV were associated 
with an increased risk of rapid CD4+ cell count decline. In the multivariate logistic 
regression only ARV remained significantly associated with increased risk for rapid 
decline.  
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 In the bivariate logistic analysis among this sub population where slope was 
estimated using mixed effects methods only receipt of ARV was associated with an 
increased risk of rapid CD4+ count decline. ARV remained the only significant factor in 
the multivariate model. Similar results from both linear regression analysis and mixed 
effects models were observed. 
 
4.8.29. Subgroup of Patients with First CD4+ Count %  350 cells/mm3 
An identical analysis of which the results are presented in sections 4.7.1. through 
4.7.28. was undertaken among patients with an initial CD4+ of at least 350 cells/mm3 or 
greater. 
 
4.8.30. Results of Bivariate Logistic Regression Models among Subgroup of Patients 
with First CD4+ Count %  350 cells/mm3 
 
4.8.31. Linear Regression 
Among patients with an initial CD4+ count equal to or greater than 350 cells and 
at least 3 recorded CD4+ counts while not receiving ARV rapid decline was defined as a 
slope, as determined by linear regression analysis, of $ -12.01 cells/mm3 per month and 
slow decline was defined by a slope of # - 2.29 cells/mm3 per month. By this definition 
27 patients were identified as showing a rapid rate of CD4+ decline and 27 patients were 
identified as showing a slow rate of CD4+ decline.  Therefore, a total of 54 patients were 
included in this analysis.  
 
 108 
4.8.32. Summary of Bivariate Analysis among Patients with First CD4+ Count ! 350 
cells/mm3, where Slope was Estimated using Linear Regression 
In a bivariate analysis of each variable of interest only receipt of ARV (OR=3.57, 
p=0.03) was associated with a greater likelihood of showing a rapid rate of CD4+ 
progression. Gender (OR=1.35, p=0.59), age at diagnosis (OR=1.00, p=0.95), ethnicity 
(OR= 1.48, p=0.51), HCV (OR=3.04, p=0.10), IDU (OR=3.38, p=0.07), Case 
management (OR=1.00, p=0.99), social assistance (OR=1.60, p=0.40), incarceration 
(OR=2.06, p=0.24) and STI co-infection (OR=0.49, p=0.24) were not shown to 
significantly influence the risk of CD4+ count rapid decline. Bivariate analysis results for 
each factor of interest are summarized in Table 4.13.  
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* OR=Odds ratio 
** CI=Confidence Interval 
 
4.8.33. Summary of Multivariate Analysis among Patients with First CD4+ Count ! 
350 cells/mm3, where Slope was Estimated using Linear Regression 
Given a p-value of less than 0.25 HCV co-infection, a history of IDU, a record of 
incarceration, STI infection and receipt of ARV were eligible for inclusion in the 
multivariate model. In constructing the multivariate logistic regression models for this 
Table 4.13. Bivariate analysis of variables of interest among patients with a first CD4+ count ! 350 
cells , where slope was estimated using linear regression (n=54). 
 
Covariates 
 
OR* 
 
95% CI** 
 
P-value 
 
 
Gender 
 
 
1.35 
 
(0.46, 3.93) 
 
0.59 
 
Age at diagnosis 
 
 
1.00 
 
(0.95, 1.05) 
 
0.95 
 
First Nations or Métis 
Ethnicity 
 
 
1.48 
 
(0.46, 4.78) 
 
0.51 
 
HCV  
 
3.04 
 
(0.80, 11.55) 
 
 
0.10 
 
IDU 
 
 
3.38 
 
(0.91, 12.64) 
 
0.07 
 
Case Management 
 
 
1.00 
 
(0.18, 5.46) 
 
0.99 
 
Social Assistance 
 
 
1.60 
 
(0.53, 4.82) 
 
0.40 
 
Incarceration 
 
 
2.06 
 
(0.62, 6.82) 
 
0.24 
 
STI 
 
 
0.49 
 
(0.15, 1.61) 
 
0.24 
 
ARV 
 
 
3.57 
 
(1.13, 11.25) 
 
0.03 
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analysis separate models were fit for HCV co-infection and IDU, due to the high degree 
of colinearity between these two variables. In the final multivariate models a history of 
IDU (OR = 4.10, p =0.052) and HCV co-infection (OR= 3.80, p = 0.07) approached 
statistical significance, however only ARV (OR = 4.15, p=0.02; OR = 3.99, p=0.027) 
remained significantly associated with an increased likelihood of rapid CD4+ cell count 
decline. Incarceration and STI infection were not significantly associated with increased 
risk of rapid CD4+ decline. A summary of this analysis is presented in Table 4.14. 
* OR=Odds ratio 
** CI=Confidence Interval 
 
4.8.34. Mixed Effects Model 
Among patients with an initial CD4+ count of 350 cells or greater using a mixed 
effects model to determine individuals showing rapid and slow rates of CD4+ cell count 
decline among CD4+ counts recorded while patients were not receiving ARV, rapid 
decline was defined as a slope of $ -3.71 cells/mm3 per month and slow decline a slope of 
# 2.64 cells/mm3 per month. A total of 87 individuals were included in this analysis, 44 
individuals with a rapid rate of decline and 43 with a slow rate of decline.  
 
Table 4.14. Multivariate model among patients with an initial CD4+ % 350, where slope was estimated 
using linear regression (n=54). 
  
Covariates 
 
 
OR 
 
95% CI 
 
p-value 
 
IDU 
 
ARV 
 
 
4.10 
 
4.15 
 
(0.99, 17.01) 
 
(1.22, 14.17) 
 
0.052 
 
0.02 
 
Rapid decline " -12.01 cells/mm3 
per month 
 
Slow decline ! -2.29 cells/mm3 per 
month 
 
 
HCV 
 
ARV 
 
 
3.80 
 
3.99 
 
(0.90, 16.05) 
 
(1.17, 13.65) 
 
0.07 
 
0.027 
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4.8.35. Summary of Results of Logistic Regression among Patients with Initial CD4+ 
Count ! 350 cells/mm3 
In the bivariate analysis patients that would eventually receive ARV were more 
likely to be identified as having a rapid rate of CD4+ decline (OR 5.54, p=value=0.0003). 
Gender (OR=1.15, p=0.74), age at diagnosis (OR=1.00, p=0.90), ethnicity (OR=1.13, 
p=0.81), HCV (OR=2.70, p=0.09), IDU (OR=1.95, p=0.19), case management 
(OR=0.97, p=0.97), receipt of social assistance (OR=1.02, p=0.96), incarceration 
(OR=1.08,p= 0.87), or co-infection with an STI (OR=1.18, p=0.72) did not significantly 
influence the risk of CD4+ count rapid decline in this population. This bivariate analysis 
for variables of interest is summarized in Table 4.15.  
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*OR= Odds Ratio 
**CI= confidence interval 
 
4.8.36. Summary of Multivariate Models among Patients with First CD4+ Count ! 
350 cells/mm3, where Slope was Estimated using Mixed Effects 
HCV co-infection and a history of IDU were eligible for inclusion in the 
multivariate model given a p-value of less than 0.25 in the bivariate analysis. In 
constructing the multivariate logistic regression models for this analysis separate models 
were fit for these two variables due to their high degree of colinearity. Receipt of ARV 
(OR=5.52, p =0.0003; OR = 6.34, p=0.0002) was a significantly associated with an 
Table 4.15. Bivariate analysis of factors of interest among patients with a first CD4+ count ! 350 cells , 
where CD4+ count slope was estimated by mixed effects models (n=87). 
Covariates OR* 95% CI**  P-value 
 
Gender 
 
 
1.15 
 
(0.50, 2.67) 
 
0.74 
 
Age at diagnosis 
 
 
1.00 
 
(0.96, 1.04) 
 
0.90 
 
First Nations or Métis 
Ethnicity 
 
 
1.13 
 
(0.44, 2.90) 
 
0.81 
 
HCV  
 
 
2.70 
 
(0.85, 8.59) 
 
0.09 
 
History of IDU 
 
 
1.95 
 
(0.71, 5.33) 
 
0.19 
 
Case Management 
 
 
0.97 
 
(0.29, 3.29) 
 
0.97 
 
Social Assistance 
 
 
1.02 
 
(0.43, 2.44) 
 
0.96 
 
Incarceration 
 
 
1.08 
 
(0.43, 2.74) 
 
0.87 
 
STI 
 
 
1.18 
 
(0.49, 2.81) 
 
0.72 
 
ARV 
 
 
5.54 
 
(2.20, 13.89) 
 
0.0003 
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increased risk of rapid CD4+ count decline. HCV co-infection (OR =3.39, p=0.06) 
approached statistical significance, whereas a history of IDU (OR= 1.93, p=0.24) did not. 
The results of these multivariate models are summarized in Table 4.16. 
 
*OR= Odds Ratio 
**CI= confidence interval 
 
 
 
4.7.37. Summary of Results of Logistic Regression among Patients with Initial CD4+ 
Count ! 350 cells/mm3 
 Receipt of ARV was significantly associated with an increased risk of rapid CD4+ 
count decline in bivariate logistic regression analysis where slope of CD4+ count was 
defined using both linear regression and mixed effects models. ARV was also the only 
significant cofactor in the multivariate models, again where CD4+ count slope was 
defined by both linear regression and mixed effects models.  
  
4.7.38. Overall Conclusion for Objective 3 
The results from the two subgroups, one with an initial CD4+ # 500 and the other with an 
initial CD4+  # 350 were similar. When CD4+ count slope was estimated by both linear 
Table 4.16. Multivariate model among patients with an initial CD4+ % 350, where CD4+ count slope was 
estimated using mixed effects models (n=87). 
  Covariates 
 
 
OR* 
 
95% CI ** 
 
p-value 
 
IDU 
 
ARV 
 
 
1.93 
 
5.52 
 
(0.65, 5.78) 
 
(2.18, 13.97) 
 
0.24 
 
0.0003 
 
Rapid " - 3.71 cells/mm3 per month 
 
Slow ! 2.64 cells/mm3 per month 
 
HCV 
 
ARV 
 
 
3.39 
 
6.34 
 
(0.94, 12.23) 
 
(2.40, 16.77) 
 
0.06 
 
0.0002 
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regression and mixed effects model ARV was the only significant factor to consistently 
distinguish between slow and fast rate in CD4+ count decline.   
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5. Discussion 
5.1.Summary of Findings 
This study is a retrospective longitudinal cohort study of 457 HIV positive patients 
diagnosed between January 1st, 2003 and November 30th, 2011 at the PLP and WSCC in 
Saskatoon, Saskatchewan. In this study we investigated the suspected phenomenon of a 
high prevalence of rapid progression to AIDS and death in Saskatoon, Saskatchewan. The 
primary objective of this study was to identify clinical and social factors associated with 
accelerated rates of decline in CD4+ counts among individual patients.  
Estimates of CD4+ slope obtained by linear regression analysis identified patients in 
possession of the following characteristics: HCV co-infection, a history of IDU, 
incarceration during follow-up, and not receiving ARV as likely to experience 
significantly steeper rates of CD4+ decline. Subsequently, patient CD4+ counts were 
modeled longitudinally. Mixed effects models identified individuals who self-identified 
as being of First Nations or Métis ethnicity, HCV co-infection, a history of IDU and 
receipt of social assistance to be independently associated with CD4+ count in 
multivariate models. Whereas receipt of ARV was significantly associated with a positive 
CD4+ count slope. Finally, a logistic regression model with the outcome of rapid versus 
slow rate of CD4+ decline, based on the 25% steepest as compared to the 25% shallowest 
slopes, found receipt of social assistance and receipt of ARV to be significantly 
associated with an increased likelihood of being classified as having a rapid rate of CD4+ 
decline in bivariate analysis. In multivariate logistic regression only the receipt of ARV 
remained significantly associated with an increased likelihood of experiencing rapid 
CD4+ count decline.   
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5.2. Demographic Factors 
The proportion of individuals in this cohort who self-identified as being of First 
Nations, Métis or Inuit ethnicity is significantly greater than in any other study cohort of 
HIV infected patients in Canada, as was the proportion of patients identifying as female 
(40,64,68). For example, in an Ontario study examining social and economic inequities 
among HIV-infected First Nations, Inuit and Métis peoples as compared to individuals of 
other ethnicities, 15% of participants were of First Nations, Inuit or Métis and 85% were 
Caucasian (40). As compared to our study population where 71 % of participants self-
identified as being of First Nations or Métis ethnicity and only 24% as Caucasian.  
As previously mentioned, another unique characteristic of the HIV infected 
population in Saskatchewan, and in the city of Saskatoon, is the high proportion of cases 
attributed to exposure through IDU. This same trend was seen in the neighboring 
province of Alberta in a study published in 2011 using data collected by the Northern 
Alberta HIV Program (NAHIVP) (64). Although the percent of individuals exposed to 
HIV through IDU was much higher in our study population. In summary, the proportion 
of cases attributed to IDU in our study is much higher than in any other HIV infected 
population in the literature (49,67) 
Due to the high association between HCV infection and IDU in our study population 
it is not possible to distinguish the independent influence of either of these variables on 
CD4+ count. As is seen in Figure 4.1, only one patient who had a history of IDU was not 
also co-infected with HCV and only six patients who were infected with HCV had no 
history of IDU. This result is not surprising due to the increased ease of transmission of 
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HCV as compared to HIV and to the sharing of needles and other drug paraphernalia as 
modes of transmission for these two viruses (5,66,79).  
 
5.3. Factors Associated with More Rapid CD4+ Decline as Estimated by Linear 
Regression  
 Linear regression was used as an exploratory analyses in Study objective 1 to 
identify cofactors which might be identified as significant in analyses performed in 
response to subsequent study objectives. The use of linear regression to models estimate 
the slope of CD4+ counts collected from patients in a longitudinal study is not without 
precedent in HIV research literature (19,78).  
In this section we will examine each of the statistical assumptions of the linear 
regression model to see which of the assumptions are met and which are violated when 
we model our longitudinal CD4+ count data using this method. The first statistical 
assumption of a linear regression model is the assumption of existence and this 
assumption is met with our data. The second assumption is the assumption of 
independence. This second assumption is violated in our study as the Y-values (CD4+ 
count) are not statistically independent of one another; an association exists between 
multiple CD4+ counts taken at different times from the same individual. The third 
statistical assumption of the linear regression model is the assumption of linearity, 
whereby the mean value of the dependent variable (CD4+ count in this study) is a linear 
function of independent variables. We have tested this assumption by plotting the CD4+ 
counts of sets of 10 randomly selected patients over month since diagnosis (see Figure 
4.2). By examining Figure 4.2 it is seen that this assumption of linearity is met in our 
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study. The fourth statistical assumption of a linear regression model is homoscedasticity, 
the assumption of equal variances for the dependent variable for any given independent 
variable. It was not practical to assess this assumption as we would have to assess equal 
variance of errors for the dependent variables of 411 different patients. The fifth 
statistical assumption of a linear regression is normality, a normal distribution of the 
dependent variable for a fixed value of an independent variable. CD4+ count values were 
graphed to test this assumption. The assumption of a normal distribution of CD4+ count 
was not seen to be overtly violated. Furthermore, neither log transforming nor taking the 
square root of CD4+ count was seen to improve normality of this dependent variable, 
therefore it was analyzed in its untransformed state. 
Cofactors identified as significantly associated with a significantly more rapid rate 
of CD4+ count decline as estimated using a linear regression model included, HCV co-
infection, a history of IDU, being incarcerated during follow-up and not receiving ARV. 
Each of these factors has previously shown associations with each other in other 
published studies. For example, HIV and HCV are both transmitted through IDU (67,76-
78). Also, there is an increased frequency of IDU among incarcerated populations, as 
patients with more extreme addictions may be at an increased likelihood to incur criminal 
charges(92,93). Finally, both IDU and incarceration has been found to be associated with 
a lower uptake of and adherence to ARV (50,52,64,73,101).  
Dorrucci et al. (1995) also compared the slopes of CD4+ count as estimated by 
linear regression among HIV patients with at least 3 recorded counts among HCV co-
infected and HCV uninfected patients. However, in contrast to our findings, these 
researchers found no significant difference between the distributions of the estimated 
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linear regression slopes in the two groups. Discrepancy in these findings as compared to 
those among our study population might be explained by differing prevalence of HIV 
transmission mode between the two populations. Where our population had a larger 
proportion of patients reporting IDU as their mode of HIV transmission and a much 
smaller population reported MSM. HCV co-infection among IDU in our study population 
was approximately 99 % and the co-occurrence of these factors may lead to an 
accelerated rate of decline, or IDU may be solely responsible for the accelerated decline.  
In our study IDUs had a higher estimated CD4+ at diagnosis. This observation 
might be explained by an increased likelihood of testing at needle exchanges and of being 
identified as a high-risk individual, leading to an HIV diagnosis earlier in the clinical 
course of the disease. As IDU are at a substantially increased risk for co-infection with 
HCV, the representation of IDU among the HCV co-infected population likely also 
explains the higher CD4+ count at time of diagnosis among HCV co-infected patients as 
compared to HCV uninfected patients. 
Griffin et al.’s (1996) study of HIV-infected incarcerated inmates found a mean 
CD4+ cell count decrease of 10.5 cells/ month during the first three months of 
incarceration and a subsequent 17 cells/month decrease over the following 7 months 
among patients who were not on ARV (19). The follow-up period of this study was only 
1 year due to the fact that most inmates were transferred to a state prison or released 
within this time period. In our study the average decrease in CD4+ count among patients 
incarcerated during follow-up was a decrease of 3.26 cells/mm3 month. However, our 
analyses includes all patients with at least 3-recorded CD4+ counts regardless of ARV 
status. Additionally, the mean patient follow-up time in our study was 3.9 years. These 
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two factors might account for differences in the rate of decrease seen in the present study 
as compared to that found by Griffin et. al. (1996). Nevertheless, in both ours and Griffin 
et. al.’s (1996) study, incarceration during follow-up was associated with a more rapid 
decrease in CD4+ count. The stress of the prison environment has been found to 
contribute to a faster rate of decline in CD4+ count among prisoners than would be 
expected in a clinic environment (19). Another hypothesis to explain this association 
might be the increased prevalence of IDU among prisoners (92,93)  
Following patients who are incarcerated has been identified as a significant 
obstacle to ensuring continuity of care among the HIV positive patients in Saskatoon. As 
previously mentioned, an estimated one third of WSCC patients have a history of 
incarceration (42). The tracking of patients through the prison systems in this province 
has been identified as a barrier to ensuring continuity of care among incarcerated HIV-
positive individuals, in particular in ensuring continual supply of ARV. This reduced 
ability to track a patient’s incarceration, duration and release also likely led to an 
underrepresentation of the true prevalence of incarceration in this study population.  
 
5.4. Factors Associated with More Rapid CD4+ Decline with Longitudinal Modeling   
When we modeled patients’ CD4+ count using linear regression in our exploratory 
analysis we ignored the correlations that exist among repeated CD4+ counts collect from 
a given patient. Statistical consequences of ignoring these correlations include incorrect 
estimates of # values through incorrect inferences and less precise estimates as well 
increasing bias in regression parameters caused by CD4+ counts missing in the data set. 
CD4+ counts may be missing from the data set for multiple reasons, for example patients 
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may have been deceased before the end of the follow-up period, may have been lost to 
follow-up, or simply may have failed to attend their scheduled clinic appointment. The 
use of mixed effects models allow for consideration of the correlation structure present 
within repeated measurements taken for a given patient as well as accounts for missing 
values among the dependent variable.  
In these analyses, as well as the analyses conducted in objective 3, age was 
included as a continuous variable as a difference in age of one year in this cohort may be 
clinically significant.  
The mixed effects model, which was found to best estimate rate of change in 
CD4+ count, was model 1 containing ethnicity. It is hypothesized that this may be due to 
the fact that as mentioned in the previous section, HCV co-infection is associated with 
IDU, which is also the exposure to which the largest proportion of HIV infections among 
First Nations or Métis people is attributed. The First Nations and Métis ethnicity factor 
also likely takes into account the impoverished living conditions due to the inferior 
economic and social conditions, which unfortunately are prevalent among First Nations 
or Métis communities, or to ongoing IDU. 
Limitations in the study dataset make comparison with other studies difficult. In 
particular unknown dates of seroconversion among this population make comparisons 
between CD4+ slopes estimated in the analysis of this study data and estimated slopes in 
other studies inappropriate. Were more simple comparisons possible conclusions about 
the presence of rapid progression among HIV infected patients in Saskatoon could be 
more easily reached. Estimates of average declines in CD4+ count among other cohorts 
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provided here. Lewden et al (2010) found an average decline in CD4+ count, while not on 
ARV, as estimated by mixed effect models, among two cohorts in Cote d’Ivoire and 
France of  -63 cells/mm3 per year (95% CI = -80, -46) among individuals enrolled in care 
6 months after seroconversion (110). Deeks et al (2004), also using mixed effects 
modeling, found a mean decrease of 8 CD4+ cells/mm3 per month (- 96 cells/ mm3 per 
year) among untreated patients in their San Francisco based cohort. Inclusion criteria for 
their study consisted of evidence of acute or recent HIV infection. When we examine the 
results of our mixed effects models we see an average rate of monthly decline among 
ARV naive patients of between -2.23 cells/mm3 and -2.65 cells/mm3, depending on 
which of the three multivariate mixed effects models we employ. This is an average 
yearly decline of between – 26.76 cells/mm3 and – 31.8 cells/mm3. Therefore, our study 
population has a shallower slope of annual decline in CD4+ count as compared to these 
two published studies. However, we must note, as mentioned above, that we have 
unknown seroconversion dates among our study, whereas patients in these published 
studies had known dates of seroconversion.  
 When comparing findings from our study regarding individual cofactors 
significantly influencing trends in CD4+ count, Staples et al (1999) found no difference in 
mean or median values of CD4+ count between HCV co-infected and HCV uninfected 
patients in their study among patients followed at the Atlanta Veterans Affairs Medical 
Center. However, out of 350 patients in their cohort only 70 were IDU (77). In our study 
we found that mean CD4+ count decline was more rapid among HCV co-infected as 
compared to uninfected individuals.  
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 Further difficulties in assessing the impacts of HCV co-infection on trends in 
CD4+ counts are the unknown dates of HCV infection as well as HIV infection. This 
same limitation was identified in a study by Piroth et al (2000). Therefore, the duration 
that these two infections have co-occurred in an individual patient is unknown, and the 
time that an individual’s immune system has been infected with these two viruses is 
unknown.  
Caution in interpreting the results of estimates of the effects of case management 
on CD4+ slope is required as the number of clients was small and the timing of entry into 
the program was not recorded in this dataset. We cannot reject the hypothesis that case 
management may be a mitigating factor in slowing CD4+ cell decline (which would be 
the desired outcome of such a program using the outcome measure in the current study to 
gauge its success) as we do not known the time at which this intervention occurred. 
Additionally, the small sample may not have allowed for sufficient power to ascertain 
differences in rate of CD4+ decline between clients and non-clients.  
 Among recipients of social assistance, it is suspected that the number of people 
recorded as being recipients of social assistance is likely an underrepresentation of the 
true number of individuals among this population who are beneficiaries of this service. 
Patients in our study have many social and medical needs and therefore likely access care 
at other clinics or through social services. Information on the receipt of social assistance 
was for the most part derived from the inclusion of physician completed forms with 
patient charts requesting additionally funds due to debilitations associated with advanced 
HIV or other medical conditions. Patients in our study may have accessed social 
assistance funds at other locations, and this information may not have been accurately 
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recorded in reviewed charts. Furthermore, advancing disease progression has been 
associated with a lowering in SES (95). Therefore, it may be difficult to determine if a 
lower SES contributed to accelerated CD4+ cell decline or whether an accelerated CD4+ 
decline necessitated receipt of social assistance.   
 
5.5. Identification of Patients with Rapid Decline in CD4+ Count 
The number of studies published focusing specifically on defining rapid CD4+ 
cell count decline was quite limited. When definitions of slow or rapid progression were 
provided they were most often specific to the given study population and therefore likely 
not generalizable to other population, especially one as unique as ours (38). It was 
challenging to identify rapid progressors among this population as seroconversion date 
was not known for every patient. Therefore, it was not possible to calculate slope of 
CD4+ over the entire course of HIV infection, because the duration of infection was 
unknown. Identification of rapid progressors was further complicated by the finding that 
91 patients had an initial CD4+ count equal to or below 200 cells/ mm3, therefore the 
immune systems of these patients were already severely compromised. Including these 
patients in an analysis to identify rapid progressors was problematic as due to their 
depressed CD4+ count their calculated slope would likely either remain stable or increase. 
As such, in primary analyses, these patients who were at the most advanced stage of HIV 
progression were classified as slow progressors. This was an erroneous classification as 
these patients had already progressed to immunological AIDS.  
Delays in testing among at risk populations and subsequent delays in presentation 
to care among infected individuals is an important obstacle in the management of the 
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HIV epidemic particularly in developed countries (22)  The occurrence of individuals 
who are first diagnosed as HIV positive at the same time as they receive an AIDS 
diagnoses is a major concern and the SHR has identified this as such (43). Kissingger et 
al (1995) found that the most severely immunocompromised clients were more likely to 
miss scheduled clinic visits (57). Severity of immunosuppression at initiation of ARV has 
previously been associated with the likelihood of immune recovery, with a rise in CD4+ 
count occurring more frequently in patients with higher CD4+ counts at the initiation of 
ARV (23). Therefore, it is important to initiate ARV at the clinically appropriate time in 
HIV disease progression in order to maximize the likelihood of immune recovery and 
subsequent maintenance of a healthy immune system in an HIV infected patient. If HIV 
is not diagnosed early in its clinical course and/ or if patients are not followed by 
clinicians at appropriate intervals, the likelihood of prevention of progression to AIDS is 
reduced, not to mention the substantially increased costs of treating an AIDS patient in 
hospital as opposed to an HIV patient in an outpatient setting (57).  Krentz, Auld and Gill 
(2004) calculated the direct costs of care in the 12 months following HIV-diagnosis in 
Southern Alberta for patients presenting with a CD4+ count below 200 cells/ !L to be 
more than twice that of a patient presenting with a CD4+ count above 200 cells/!L (111) 
 Due to the unavailability of date of seroconversion among all patients and 
therefore an inability to accurate define duration of HIV infection rapid and slow 
progression was assessed among two sub group of patients with initial CD4+ counts equal 
to or greater than 500 and 350 cells/mm3. These values were selected because a CD4+ 
count of 500 or greater is associated with a normal life expectancy among HIV infected 
patients and initiation of ARV is recommended before CD4+ count declines below 350 
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cells (9). Therefore, patients who entered care above these CD4+ counts were more likely 
to record CD4+ counts prior to initiation of ARV, therefore allowing for observation of 
the natural course of HIV infection. In addition, we estimated CD4+ count slope using 
two methods, linear regression and mixed effects models. Under the circumstances of this 
analyses the assumption of a linear relationship between the independent and dependent 
variables is justified as CD4+ counts included in this analysis are those recorded while 
patients were not on ARV and it is reasonable to expect that CD4+ counts should show a 
linear pattern of decline prior to initiation of ARV. The use of two statistical methods to 
estimate CD4+ count slope is further justified by an absence in the literature of any 
precedent of methods by which patients should be identified as rapid progressors and 
how rapid progression should be defined with respect to CD4+ count. In our analyses 
similar results were obtained between the two CD4+ count slope estimation methods this 
consistency allows for a higher level of confidence in our results.  
In this analysis only CD4+ counts of patients who did not receive ARV during the 
follow-up period and CD4+ counts of patients who were prescribed ARV recorded before 
the date of ARV initiation were used. Other authors have also restricted evaluation of 
CD4+ cell count slopes over time to participants with initial CD4+ counts greater than 500 
in order to minimize the number or participants likely to initiate ARV after their baseline 
visit (20).  Although this inclusion criteria reduced the study sample size it resolved the 
issue of the erroneous classification of end stage HIV patients as slow progressors.  
 Co-infection with HCV, a history of IDU and receipt of ARV were the variables 
most strongly associated with an increased likelihood of having a rapid rate of CD4+ 
decline, although only receipt of ARV was statistically significant. This may indicate that 
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patients exhibiting rapid CD4+ count decline were more likely to be prescribed ARV or 
were more likely to progress to a CD4+ count at which initiation of ARV was 
recommended. Receipt of social assistance was significantly associated with an increased 
likelihood of rapid CD4+ decline among patients with an initial CD4+ count of equal to or 
greater than 500 where slope was estimating using linear regression in bivariate analysis.  
  In our study median rate of decline, estimated by linear regression, among 
patients with at least 3 CD4+ counts recorded among patients who did not receive ARV 
during the follow-up period were similar between the two sub-groups. Among patients 
with an initial CD4+ count of 500 cells or greater, median rate of decline was - 6.85 
cells/mm3 per month and among patients with an initial CD4+ count of 350 cells or 
greater median rate of decline was -6.45 cells/month. Easterbrook et al (1993) included 
patients with at least 3 CD4+ counts recorded prior to initiation of therapy to determine a 
median rate of decrease of 4-11 cells per month as determined by linear regression 
stratified by CD4+ count at initiation ARV, which is consistent with our study (23). In 
another study using data from the ongoing MACS cohort of homosexual and bisexual 
men collected before January 1990, in order to avoid influence of ARV, a highly 
significant linear decline of 109 cells/mm3 per year in the first 3 years of follow-up after 
seroconversion was observed (21). The rates of decline in CD4+ count in our study are 
comparable to those recorded by Easterbrook and slightly less than those found in the 
MACS study. However, the validity of comparing the CD4+ slopes estimated in our study 
to these analyses of data collected in the late 1980s and early 1990s is questionable as the 
characteristics of patients not receiving ARV are likely different. Among our study 
population, effective ARV was widely available and patients meeting immunological 
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guidelines for the initiation of ARV were in high likelihood recipients of this therapy. 
Patients who did not receive ARV during the follow-up time were likely those whose 
CD4+ were sufficiently elevated to levels where ARV is not required. Whereas, in the 
studies from the late 1980s and early 1990s effective ARV may not have been available 
to all patients and consequently despite recording CD4+ counts where ARV would have 
been recommended by today’s guidelines these patients likely did not receive such 
therapies.  
 
5.6. Clinical Implications of Findings 
It is important that the findings of our study be beneficial to the patients enrolled in 
this study cohort. Due to the nature of this study these benefits are primarily in improving 
clinical practices. An essential goal of our study was to contribute information to aid 
clinicians in the identification of patients in Saskatoon at risk of rapid progression based 
on the individual social and clinical characteristics of patients. The identification of 
cofactors in progression to AIDS and/or death has the potential to slow disease 
progression if the impacts of such cofactors can be mitigated (12). The presence of 
coinfections or a high risk of certain opportunistic diseases, can provide a strong rationale 
for earlier initiation of therapy (9). Early and more aggressive ARV might be beneficial 
to patients with more rapid disease progression (23). 
 The mixed effects models built in our study have the potential to be developed 
into a clinical tools for use by clinical care providers in predicting CD4+ counts of 
patients at follow-up visits. By such means patients at particular risk of attaining low 
CD4+ counts in relatively short time intervals could be identified and steps could be taken 
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to mitigate this risk and/ or to prepare patients for initiation of ARV. For example, 
although we did not see a significant association with increased CD4+ counts and 
involvement with case management services likely due to dataset limitations in our study, 
it is a reasonable expectation that enrollment in case management services should have a 
positive impact on CD4+ count. Associations with engagement in case management 
services and improvements in overall health among HIV infected individuals have been 
previously recorded (72,99,100). Through the use of such a tool clinicians would be 
better able to identify patients who would most benefit from engagement in Case 
Management services and thereby better allocate this limited resource.  
 
5.7. Study Strengths 
One of the important strengths of this study is that it investigates a unique and 
understudied population that is facing an HIV epidemic that is at present far from its 
resolution. This unique population is characterized by three important factors, each of 
which potentially place HIV infected individuals at risk for rapid progression. These 
factors include an overrepresentation of individuals of First Nations or Métis ethnicity 
and therefore the social and economic disadvantage that exists at increased rates among 
this population, and a high prevalence of HCV co infection and IDU. Additionally, the 
follow-up period of this study incorporates the course of the emergence of the dramatic 
increase in incidence of HIV in the province of Saskatchewan. This study was also set in 
the most severely affected health region in the province, as the SHR has reported the 
highest number of cases of HIV across all regional health authorities in Saskatchewan 
since 2005 (43). 
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Another strength of this study is that data was derived from patient charts complied 
by clinicians providing ongoing care to patients, therefore one can be confident that 
information contained within these charts is accurate to the best of the abilities of these 
clinicians.  
Importantly, this study advances HIV epidemiological research by contributing a 
definition of rapid HIV disease progression with respect to CD4+ count decline. Such a 
definition is valuable due to limited numbers of studies offering any definition of rapid 
progression, especially with respect to decline in CD4+ count. This study provides 
important insights into the phenomenon of rapid HIV disease progression in the province 
of Saskatchewan and in doing so has the potential to improve clinical care to these 
patients and ultimately improve their quality of life. Finally, as First Nations, Métis and 
Inuit IDU comprise the fastest growing proportion of incident HIV infections in Canada, 
a more throughout understanding of HIV disease progression among this population will 
become essential to the mitigation of the HIV epidemic in Canada (3).  
Our study results may additionally prove to be influential at a policy level if the 
conclusions drawn from the research in this study may contribute to a greater allocation 
of funding to HIV prevention and care in Saskatchewan. Furthermore, as our study 
arrives at the conclusion that the unique epidemiology of HIV in Saskatchewan does 
contribute to making this infected population one that is uniquely vulnerable 
interventions can be tailored to the most high-risk individuals among this population. For 
example, based on this study it would appear that interventions targeted at reducing HIV 
transmission via IDU in First Nations and Métis communities would be particularly 
effective in reducing HIV incidence in Saskatchewan.  
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5.8. Study Limitations  
Limitations of this study include those inherent in all retrospective studies, namely 
data was collected from a source, medical charts, not designed for scientific studies. On 
multiple occasions the data source was missing information or there was a lack of 
sufficient detail for inclusion in statistical analysis of variables of interest. In addition, 
records of patients who migrated to Saskatchewan from other provinces, territories or 
countries were often incomplete with regards to variables of interest in this study.  
A further limitation is the possible exclusion of eligible patients due to the use of 
multiple lists in the identification of patients, as no centralized list of HIV infected 
patients followed at the PLP and WSCC existed or was accessible to the M.Sc. student 
collecting the data. As consequence the student had to identify patients based on several 
master lists as created by past contributors to the database, as well as a new referrals 
binder kept by administrative assistants in the Infectious Disease Department at RUH. 
 Unknown seroconversion dates among many of the patients in the dataset is 
another important limitation of this study, as it renders investigators unable to assess 
CD4+ count decline over the entire duration of HIV infection. An absence of information 
on ARV adherence among patients receiving such therapies is another limitation in this 
study. In addition periods of discontinuation of ARV and changes in therapeutic regime 
are difficult to assess statistically and as a result were not accounted for in our study. It 
was also not possible to assess the impact of housing insecurity on CD4+ count, which is 
an important limitation in our study as a significant number of patients likely experienced 
housing insecurity. Active IDU was also absent in our analysis due to difficulties in 
assessing this variable, as a physician may not have recorded this information in a patient 
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chart or the patient may not have been seen within the past 6 months, as the definition of 
active IDU included IDU in the last 6 months. The impact of the HLA-B*57 MHC class 
type was also not investigated in this population due to the limited number of individuals 
in possession of this phenotype, despite recognition of the association of this allele with 
rapid progression to AIDS (61). Finally, we did not factor into any analyses the impact on 
population means of including individuals mentioned in the special cases section (Section 
4.2) such as pregnant women. Inclusion in analyses of individuals with other conditions 
also negatively affecting CD4+ count may have caused an overestimation of the 
magnitude of decline in CD4+ count. Were we to account for the influence of pregnancy 
on CD4+ count in our analyses we might consider either excluding pregnant females from 
the analyses or only excluding CD4+ counts recorded during time of pregnancy.  
 The impact of stressful life events as well as the loss of social support is not well 
measured in the present study. This may be a weakness of this study as many of the 
patients in this study likely have lost partners or family members, whether it be to HIV or 
another causes attributable to turbulent lives. Such losses results in both a loss of social 
support as well as represent an extremely stressful life event. Diminished social support 
and stressful life events have both been associated with lowered immunological function 
and therefore may be associated with a more rapid course of HIV infection (97,98).  
In Study Objective 3 subgroup inclusion criteria resulted in a significant reduction in 
sample size particularly when the inclusion criteria was 3 CD4+ counts recorded while 
not receiving ARV and an initial CD4+ count of # 500 cells/ mm3. In this instance the 
sample size was reduced to only 32 patients. Therefore, these analyses may not have had 
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a sufficient sample size to allow for adequate power to detect significant associations 
between cofactors and rate of CD4+ count decline. 
Another significant limitation of this study is that it is difficult statistically to measure 
the potential cumulative negative impacts of the co-occurrence within an individual of 
HCV co-infection, IDU and the social and economical disadvantages often associated 
with First Nations or Métis ethnicity on rate of CD4+ decline, due to the high colinearity 
between these three variables. In general, it was difficult to represent multiple health 
compromising conditions present amongst some patients in statistical models and even 
more difficult to evaluate the potential synergistic impacts of these conditions on CD4+ 
cell decline. It may be possible to create a function combining these three variables to be 
incorporated into one model. However, the use of such a new variable in a model to 
estimate the effect of these three highly associated cofactors is questionable. Some areas 
of concern include the unknown duration of HCV infection, an unknown duration of IDU 
as well as difficulty in accounting for the differing effects of various drugs on the 
immune system and finally in identifying the social factors that contribute to First 
Nations and Métis ethnicity influencing CD4+ count. As such we would recommend 
caution in utilizing such a variable as well as to recommend that it be validated using a 
larger data than the one in this study prior to any scientific use. This presence of co-
factors amongst a single patient, all potentially associated with accelerated CD4+ decline, 
is undoubtedly also a challenge faced by infectious disease physicians in the clinical 
management of these patients.   
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Finally, our decision to use the upper and lower quartiles of CD4+ slope to define 
rapid and slow progression in the third objective of our study was arbitrary and therefore, 
might not represent the best method by which to make such distinctions. 
 
6. Conclusion and Future Studies 
Rates of CD4+ decline among HIV-1 infected individuals vary considerably, while 
some individuals maintain stable counts for long periods of time, others experience rapid 
decline. In this study we investigated social and clinical factors that might be associated 
with some of the observed heterogeneity in rates of CD4+ cell decline with the goal of 
improving the quality of care provided to HIV infected patients in Saskatoon. In 
summary, a history of incarceration, co-infection with HCV, a history of IDU, First 
Nations and Métis ethnicity, age at diagnosis, receipt of social assistance and not 
receiving ARV had a negative influence on trends in CD4+ count. 
At the beginning of the HIV epidemic HIV-positive people were likely to die within 
10 years of infection. The development of ARV has transformed, at least for people 
living in developed countries, this infection into a chronic treatable condition. Therefore, 
decisions regarding HIV therapies are arguably of greater importance today than ever 
before in the history of the HIV/AIDS epidemic. Results of this study have the potential 
to influence physician decisions of timing of initiation of ARV. For example in this study 
a history of IDU was identified as associated with an increased risk of a rapid rate of 
decline in CD4+ count. Thereby a physician may recommend initiation of ARV at an 
earlier time for a patient with a history of IDU than for a patient without such a history, in 
order to initiate ARV at the optimal time.  
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Other research questions of interest generated over the course of the completion of 
this thesis included, whether or not ethnicity affects HIV prognosis after the initiation of 
treatment, quantifying the response of CD4+ count to treatment in this population, 
determining patient factors that predict a rise in CD4+ count to 500 cells and lastly, 
differentiating between factors that influence CD4+ rate of decline on-treatment as 
compared to off treatment. The investigation of the effects of other prevalent cofactors 
such as mental illness and smoking status, which could not be included in the current 
study due to data limitations, on rate of CD4+ decline would also be of use to clinicians as 
they plan for the clinical management of patients. Smoking, for example, has been 
associated with significantly higher CD4+ counts among HIV negative individuals (27).  
The establishment of a prospective cohort among this study population will be 
instrumental in improving the quality of data available for analysis and enabling a much 
clearer estimation of the clinical and immunological course of HIV in this population.  
The conducting of qualitative studies among this cohort would also be extremely 
powerful because of the tumultuous lives led by many of the individuals in this study. 
The stories of these individuals’ lives would give important insights into the HIV 
epidemic in Saskatchewan and hopefully lead to a strong call to action to improve the 
lives of those afflicted. Such studies would also follow the conclusions of Fee and 
Krieger (1993) that the development of more effective prevention and health care 
strategies will be greatly aided by making “…the experiences and views of those hit 
hardest by the epidemic….more central to the conduct of scientific research and the 
establishment of health policy” (102). 
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For many individuals in our study being infected with HIV is one of many challenges 
faced in daily life among others including, drug addiction, mental illness, and poverty. 
More than clinical interventions are required if there can be hope for meaningful and 
sustained improvements in these individuals’ lives. Monette et al (2011) support this 
notion that policies and services that integrate income and employment support with 
affordable and stable housing may have the potential to reduce health disparities and 
improve health outcomes for First Nations, Métis and Inuit peoples living with HIV (40). 
Fee and Krieger (1993) reiterate this notion that, “…AIDS…cannot be understood or 
addressed solely within the parameters of the health care system.” (102). Multiple and 
sustained social interventions will be required in addition to a throughout understanding 
of the clinical course of the HIV virus in Saskatoon, in order to turn the tide on the HIV 
epidemic in this city and in this province.  
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